TY  - THES
AU  - Kovačević, Milena
PY  - 2020
UR  - http://eteze.bg.ac.rs/application/showtheses?thesesId=7515
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:22401/bdef:Content/download
UR  - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=16616713
UR  - http://nardus.mpn.gov.rs/handle/123456789/17332
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3706
AB  - Lek-lek interakcije (LLI) su čest uzrok pojave neželjenih ishoda terapije kroz izmenu u efikasnosti ili bezbednosti terapije, a koji se može prevenirati. Posledice LLI nisu dovoljno istražene zbog njihovog neprepoznavanja. Lekovi u terapiji bolesti kardiovaskularnog sistema imaju veliki potencijal za stupanje u LLI, zbog svojih farmakokinetičkih i/ili farmakodinamskih karakteristika. Cilj istraživanja bila je identifikacija potencijalnih i klinički značajnih LLI, procena prevalence, karakteristika i prediktora u populaciji pacijenata sa kardiovaskularnim bolestima, kao i njihov uticaj na ishode terapije. Podaci o pacijentima su prikupljeni retrospektivno iz medicinske dokumentacije. Za identifikaciju LLI korišćena je baza Lexi-Interact, dok je statistička obrada podataka izvršena u programu PASW Statistics. Određena je visoka prevalenca potencijalno relevantnih LLI u populaciji pacijenata sa kardiovaskularnim bolestima, kako u trenutku prijema pacijenata na odeljenje kardiologije (60,7%), tako i tokom bolničkog lečenja (83,9%). Identifikovane su vrste, mehanizam, nivo rizika i stepen ozbiljnosti potencijalnih i ispoljenih LLI, identifikovani su prediktori za njihovu pojavu, izdvojene su subpopulacije pacijenata sa većom prevalencom, i ispitano je prisustvo dodatnih faktora rizika koji povećavaju rizik od manifestacije LLI. Procenjena je primena Lexi-Interact baze kao alata za identifikaciju LLI i optimizaciju terapije izborom alternativnog leka, a razmotrene su i mogućnosti unapređenja alerta uključivanjem karakteristika pacijenata kao modifikatora rizika. Prevalenca klinički značajnih LLI koje su bile povezane sa pojavom neželjenih reakcija na lek u trenutku hospitalizacije pacijenta iznosila je 9,7%. Razvijen je skor koji predviđa verovatnoću budućeg neželjenog događaja usled prisustva kumulativnog rizika od većeg broja potencijalnih LLI. Identifikacija pacijenata sa većim rizikom od pojave neželjenog događaja može olakšati prepoznavanje LLI i unaprediti primenu elektronskih baza podataka u kliničkoj praksi.
AB  - Drug-drug  interactions(DDIs) represent  one  of  the  preventable  causes  of  adverse therapy outcomes, through deteriorated efficacy and safety. The true extent of harm related to DDIs is not well established due to a lack of recognition. Cardiovascular disease (CVD) drugs are prone to interact in adverse way due to their pharmacokinetic/pharmacodynamic properties, and have been frequently implicated in adverse drug events. The study aimed to identify both potential and clinically significant DDIs, to assess their type, prevalence and predictors, and their impact on therapy outcomes. Data were retrospectively obtained from medical records. Lexi-Interact was used as the screening tool for DDIs, and statistics were performed using PASW. We found a high prevalence of potential DDIs in CVD patients: at the admission 60.7% and during hospital stay 83.9%. The study revealed the type, characteristics, risk rating and severity of DDIs; identified patients with higher exposure to DDIs, the predictors for their occurrence, as well as the presence of additional risk factors for DDIs manifestation. We assessed the utility of Lexi-Interact database in identifying potentially relevant DDIs, and the possibility of therapy optimization using an alternative drug. Our findings indicate the necessity of including the patients laboratory results or clinical data as DDIs risk modifier, to improve DDIs alert quality. DDI-related adverse drug reactions were found in 9.7% of patients at the admission. Given the high prevalence of CVD, DDI-related harm might be a significant burden worldwide. A prediction tool was developed to identify patients having high cumulative risk for the occurrence of an adverse event due to DDIs. Identification of high-risk patients might ease the recognition of DDI-related harm and improve the use of electronic databases in clinical practice.
PB  - Универзитет у Београду, Фармацеутски факултет
T2  - Универзитет у Београду
T1  - Procena učestalosti i prediktora klinički značajnih lek-lek interakcija i njihov uticaj na ishode terapije pacijenata sa kardiovaskularnim oboljenjima
UR  - https://hdl.handle.net/21.15107/rcub_nardus_17332
ER  - 

@phdthesis{
author = "Kovačević, Milena",
year = "2020",
abstract = "Lek-lek interakcije (LLI) su čest uzrok pojave neželjenih ishoda terapije kroz izmenu u efikasnosti ili bezbednosti terapije, a koji se može prevenirati. Posledice LLI nisu dovoljno istražene zbog njihovog neprepoznavanja. Lekovi u terapiji bolesti kardiovaskularnog sistema imaju veliki potencijal za stupanje u LLI, zbog svojih farmakokinetičkih i/ili farmakodinamskih karakteristika. Cilj istraživanja bila je identifikacija potencijalnih i klinički značajnih LLI, procena prevalence, karakteristika i prediktora u populaciji pacijenata sa kardiovaskularnim bolestima, kao i njihov uticaj na ishode terapije. Podaci o pacijentima su prikupljeni retrospektivno iz medicinske dokumentacije. Za identifikaciju LLI korišćena je baza Lexi-Interact, dok je statistička obrada podataka izvršena u programu PASW Statistics. Određena je visoka prevalenca potencijalno relevantnih LLI u populaciji pacijenata sa kardiovaskularnim bolestima, kako u trenutku prijema pacijenata na odeljenje kardiologije (60,7%), tako i tokom bolničkog lečenja (83,9%). Identifikovane su vrste, mehanizam, nivo rizika i stepen ozbiljnosti potencijalnih i ispoljenih LLI, identifikovani su prediktori za njihovu pojavu, izdvojene su subpopulacije pacijenata sa većom prevalencom, i ispitano je prisustvo dodatnih faktora rizika koji povećavaju rizik od manifestacije LLI. Procenjena je primena Lexi-Interact baze kao alata za identifikaciju LLI i optimizaciju terapije izborom alternativnog leka, a razmotrene su i mogućnosti unapređenja alerta uključivanjem karakteristika pacijenata kao modifikatora rizika. Prevalenca klinički značajnih LLI koje su bile povezane sa pojavom neželjenih reakcija na lek u trenutku hospitalizacije pacijenta iznosila je 9,7%. Razvijen je skor koji predviđa verovatnoću budućeg neželjenog događaja usled prisustva kumulativnog rizika od većeg broja potencijalnih LLI. Identifikacija pacijenata sa većim rizikom od pojave neželjenog događaja može olakšati prepoznavanje LLI i unaprediti primenu elektronskih baza podataka u kliničkoj praksi., Drug-drug  interactions(DDIs) represent  one  of  the  preventable  causes  of  adverse therapy outcomes, through deteriorated efficacy and safety. The true extent of harm related to DDIs is not well established due to a lack of recognition. Cardiovascular disease (CVD) drugs are prone to interact in adverse way due to their pharmacokinetic/pharmacodynamic properties, and have been frequently implicated in adverse drug events. The study aimed to identify both potential and clinically significant DDIs, to assess their type, prevalence and predictors, and their impact on therapy outcomes. Data were retrospectively obtained from medical records. Lexi-Interact was used as the screening tool for DDIs, and statistics were performed using PASW. We found a high prevalence of potential DDIs in CVD patients: at the admission 60.7% and during hospital stay 83.9%. The study revealed the type, characteristics, risk rating and severity of DDIs; identified patients with higher exposure to DDIs, the predictors for their occurrence, as well as the presence of additional risk factors for DDIs manifestation. We assessed the utility of Lexi-Interact database in identifying potentially relevant DDIs, and the possibility of therapy optimization using an alternative drug. Our findings indicate the necessity of including the patients laboratory results or clinical data as DDIs risk modifier, to improve DDIs alert quality. DDI-related adverse drug reactions were found in 9.7% of patients at the admission. Given the high prevalence of CVD, DDI-related harm might be a significant burden worldwide. A prediction tool was developed to identify patients having high cumulative risk for the occurrence of an adverse event due to DDIs. Identification of high-risk patients might ease the recognition of DDI-related harm and improve the use of electronic databases in clinical practice.",
publisher = "Универзитет у Београду, Фармацеутски факултет",
journal = "Универзитет у Београду",
title = "Procena učestalosti i prediktora klinički značajnih lek-lek interakcija i njihov uticaj na ishode terapije pacijenata sa kardiovaskularnim oboljenjima",
url = "https://hdl.handle.net/21.15107/rcub_nardus_17332"
}

Kovačević, M.. (2020). Procena učestalosti i prediktora klinički značajnih lek-lek interakcija i njihov uticaj na ishode terapije pacijenata sa kardiovaskularnim oboljenjima. in Универзитет у Београду
Универзитет у Београду, Фармацеутски факултет..
https://hdl.handle.net/21.15107/rcub_nardus_17332

Kovačević M. Procena učestalosti i prediktora klinički značajnih lek-lek interakcija i njihov uticaj na ishode terapije pacijenata sa kardiovaskularnim oboljenjima. in Универзитет у Београду. 2020;.
https://hdl.handle.net/21.15107/rcub_nardus_17332 .

Kovačević, Milena, "Procena učestalosti i prediktora klinički značajnih lek-lek interakcija i njihov uticaj na ishode terapije pacijenata sa kardiovaskularnim oboljenjima" in Универзитет у Београду (2020),
https://hdl.handle.net/21.15107/rcub_nardus_17332 .

TY  - JOUR
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
AU  - Miljković, Branislava
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3616
AB  - Background Drug–drug interactions represent one of the causes of adverse therapy outcomes through deteriorated efficacy or safety. However, the true extent of harm related to drug–drug interactions is not well established due to a lack of recognition and understanding. Objective The aim of this study was to investigate the association of potential drug–drug interactions with patients variables recorded at admission. Setting A cross-sectional correlation study was performed on the Cardiology ward of the University Clinical Hospital Center in Belgrade, Serbia. Method Data were retrospectively obtained from medical records and LexiInteract was used as the screening tool for potential drug–drug interactions. Main outcome measure Clinical and laboratory parameters recorded at the patients admission. Results A total of 351 patient records entered the analysis, with the mean age of 70 ± 10 years. The prevalence of potentially relevant drug–drug interactions was 61% (N = 213). After controlling for patient characteristics, nine potential drug–drug interactions were significantly associated with laboratory values outside the range and five potential drug–drug interactions with inadequate clinical parameter values. Potential drug–drug interactions were associated with abnormalities in blood count, metabolic parameters, electrolyte imbalance and renal function parameters. Association with inadequate control of systolic, diastolic blood pressure, as well as heart rhythm was also shown. Conclusion Drug–drug interactions were associated with patients clinical and laboratory findings. Our findings may assist in the identification of patients with increased likelihood of suboptimal therapy outcomes. Generating evidence through post-marketing drug–drug interactions research would lead to improvement in clinical decision-support systems, increased effectiveness and utilization in everyday clinical practice.
PB  - Springer
T2  - International Journal of Clinical Pharmacy
T1  - Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission
VL  - 42
IS  - 1
SP  - 150
EP  - 157
DO  - 10.1007/s11096-019-00951-y
ER  - 

@article{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Radovanović, Slavica and Stevanović, Predrag and Miljković, Branislava",
year = "2020",
abstract = "Background Drug–drug interactions represent one of the causes of adverse therapy outcomes through deteriorated efficacy or safety. However, the true extent of harm related to drug–drug interactions is not well established due to a lack of recognition and understanding. Objective The aim of this study was to investigate the association of potential drug–drug interactions with patients variables recorded at admission. Setting A cross-sectional correlation study was performed on the Cardiology ward of the University Clinical Hospital Center in Belgrade, Serbia. Method Data were retrospectively obtained from medical records and LexiInteract was used as the screening tool for potential drug–drug interactions. Main outcome measure Clinical and laboratory parameters recorded at the patients admission. Results A total of 351 patient records entered the analysis, with the mean age of 70 ± 10 years. The prevalence of potentially relevant drug–drug interactions was 61% (N = 213). After controlling for patient characteristics, nine potential drug–drug interactions were significantly associated with laboratory values outside the range and five potential drug–drug interactions with inadequate clinical parameter values. Potential drug–drug interactions were associated with abnormalities in blood count, metabolic parameters, electrolyte imbalance and renal function parameters. Association with inadequate control of systolic, diastolic blood pressure, as well as heart rhythm was also shown. Conclusion Drug–drug interactions were associated with patients clinical and laboratory findings. Our findings may assist in the identification of patients with increased likelihood of suboptimal therapy outcomes. Generating evidence through post-marketing drug–drug interactions research would lead to improvement in clinical decision-support systems, increased effectiveness and utilization in everyday clinical practice.",
publisher = "Springer",
journal = "International Journal of Clinical Pharmacy",
title = "Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission",
volume = "42",
number = "1",
pages = "150-157",
doi = "10.1007/s11096-019-00951-y"
}

Kovačević, M., Vezmar-Kovačević, S., Radovanović, S., Stevanović, P.,& Miljković, B.. (2020). Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission. in International Journal of Clinical Pharmacy
Springer., 42(1), 150-157.
https://doi.org/10.1007/s11096-019-00951-y

Kovačević M, Vezmar-Kovačević S, Radovanović S, Stevanović P, Miljković B. Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission. in International Journal of Clinical Pharmacy. 2020;42(1):150-157.
doi:10.1007/s11096-019-00951-y .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Radovanović, Slavica, Stevanović, Predrag, Miljković, Branislava, "Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission" in International Journal of Clinical Pharmacy, 42, no. 1 (2020):150-157,
https://doi.org/10.1007/s11096-019-00951-y . .

TY  - JOUR
AU  - Škorić, Biljana
AU  - Jovanović, Marija
AU  - Miljković, Branislava
AU  - Kuzmanović, Marko
AU  - Vučićević, Katarina
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3596
AB  - High dose methotrexate (MTX) is used in therapy of acute lymphoblastic leukemia and non-Hodgkin lymphoma in pediatric patients. It acts as competitive inhibitor of dihydrofolate reductase and consequently inhibits synthesis of deoxyribonucleic acid. The bioavailability is dependent  upon  dose  and  route  of  administration.  The  drug  is  moderately  bound  to  plasma proteins and distributes in body tissues and cells. After the administration in high doses, MTX partially undergoes hepatic and intracellular metabolism, but renal excretion of parent compound is  the  main  route  of  elimination.  Numerous  factors  may  influence  pharmacokinetics  and concentration of drug,  but primarily  the effect  of renal  function on  elimination  is described. Delayed elimination might also be the consequence of drug interaction in renal tubules. Toxicity can arise with high MTX doses, especially in patients with delayed MTX elimination. Therapeutic drug monitoring is indicated due to safety reasons, in order to optimize leucovorin (folinic acid) administration as it reduces MTX toxicity. Considering the variability and the toxicity of high dose MTX therapy, special caution is required in pediatric patients.
AB  - Metotreksat (MTX) se u visokim dozama koristi u terapiji akutne limfoblastne leukemije i ne-Hodkinovog  limfoma  u  pedijatrijskoj  populaciji.  Deluje  kao  kompetitivni  inhibitor dihidrofolat reduktaze i time inhibira sintezu dezoksiribonukleinske kiseline. Stepen biološke raspoloživosti zavisi od puta primene leka i doze. Vezivanje za proteine plazme je u umerenom stepenu, a raspodeljuje se u tkiva i ćelije. Nakon primene u visokim dozama MTX delimično podleže hepatičkom i intracelularnom metabolizmu, ali glavni put eliminacije je preko bubrega u nepromenjenom obliku. Veliki broj faktora utiče na farmakokinetiku i koncentraciju leka, a pre svega je opisan uticaj funkcije bubrega na eliminaciju. Usporena eliminacija može biti i posledica interakcije sa drugim lekovima na nivou transportera u renalnim tubulima. Primena visokih doza MTX nosi rizik od pojave toksičnosti, posebno pri usporenoj eliminaciji. Terapijsko praćenje leka je indikovano iz bezbednosnih razloga, kako bi se optimizovala primena leukovorina (folinska kiselina) koji smanjuje toksičnost MTX. Imajući u vidu varijabilnost i toksičnost pri primeni visokih doza MTX poseban oprez je potreban u pedijatrijskoj populaciji pacijenata.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Clinical pharmacokinetics of methotrexate in the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma in pediatric patients
T1  - Klinička farmakokinetika metotreksata u terapiji akutne limfoblastne leukemije i ne-Hodkinovog limfoma u pedijatrijskoj populaciji pacijenata
VL  - 70
IS  - 1
SP  - 20
EP  - 23
DO  - 10.5937/arhfarm2001020X
ER  - 

@article{
author = "Škorić, Biljana and Jovanović, Marija and Miljković, Branislava and Kuzmanović, Marko and Vučićević, Katarina",
year = "2020",
abstract = "High dose methotrexate (MTX) is used in therapy of acute lymphoblastic leukemia and non-Hodgkin lymphoma in pediatric patients. It acts as competitive inhibitor of dihydrofolate reductase and consequently inhibits synthesis of deoxyribonucleic acid. The bioavailability is dependent  upon  dose  and  route  of  administration.  The  drug  is  moderately  bound  to  plasma proteins and distributes in body tissues and cells. After the administration in high doses, MTX partially undergoes hepatic and intracellular metabolism, but renal excretion of parent compound is  the  main  route  of  elimination.  Numerous  factors  may  influence  pharmacokinetics  and concentration of drug,  but primarily  the effect  of renal  function on  elimination  is described. Delayed elimination might also be the consequence of drug interaction in renal tubules. Toxicity can arise with high MTX doses, especially in patients with delayed MTX elimination. Therapeutic drug monitoring is indicated due to safety reasons, in order to optimize leucovorin (folinic acid) administration as it reduces MTX toxicity. Considering the variability and the toxicity of high dose MTX therapy, special caution is required in pediatric patients., Metotreksat (MTX) se u visokim dozama koristi u terapiji akutne limfoblastne leukemije i ne-Hodkinovog  limfoma  u  pedijatrijskoj  populaciji.  Deluje  kao  kompetitivni  inhibitor dihidrofolat reduktaze i time inhibira sintezu dezoksiribonukleinske kiseline. Stepen biološke raspoloživosti zavisi od puta primene leka i doze. Vezivanje za proteine plazme je u umerenom stepenu, a raspodeljuje se u tkiva i ćelije. Nakon primene u visokim dozama MTX delimično podleže hepatičkom i intracelularnom metabolizmu, ali glavni put eliminacije je preko bubrega u nepromenjenom obliku. Veliki broj faktora utiče na farmakokinetiku i koncentraciju leka, a pre svega je opisan uticaj funkcije bubrega na eliminaciju. Usporena eliminacija može biti i posledica interakcije sa drugim lekovima na nivou transportera u renalnim tubulima. Primena visokih doza MTX nosi rizik od pojave toksičnosti, posebno pri usporenoj eliminaciji. Terapijsko praćenje leka je indikovano iz bezbednosnih razloga, kako bi se optimizovala primena leukovorina (folinska kiselina) koji smanjuje toksičnost MTX. Imajući u vidu varijabilnost i toksičnost pri primeni visokih doza MTX poseban oprez je potreban u pedijatrijskoj populaciji pacijenata.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Clinical pharmacokinetics of methotrexate in the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma in pediatric patients, Klinička farmakokinetika metotreksata u terapiji akutne limfoblastne leukemije i ne-Hodkinovog limfoma u pedijatrijskoj populaciji pacijenata",
volume = "70",
number = "1",
pages = "20-23",
doi = "10.5937/arhfarm2001020X"
}

Škorić, B., Jovanović, M., Miljković, B., Kuzmanović, M.,& Vučićević, K.. (2020). Clinical pharmacokinetics of methotrexate in the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma in pediatric patients. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 70(1), 20-23.
https://doi.org/10.5937/arhfarm2001020X

Škorić B, Jovanović M, Miljković B, Kuzmanović M, Vučićević K. Clinical pharmacokinetics of methotrexate in the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma in pediatric patients. in Arhiv za farmaciju. 2020;70(1):20-23.
doi:10.5937/arhfarm2001020X .

Škorić, Biljana, Jovanović, Marija, Miljković, Branislava, Kuzmanović, Marko, Vučićević, Katarina, "Clinical pharmacokinetics of methotrexate in the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma in pediatric patients" in Arhiv za farmaciju, 70, no. 1 (2020):20-23,
https://doi.org/10.5937/arhfarm2001020X . .

TY  - JOUR
AU  - Miletić Vukajlović, Jadranka
AU  - Drakulić, Dunja
AU  - Pejić, Snežana
AU  - Ilić, Tihomir V.
AU  - Stefanović, Aleksandra
AU  - Petković, Marijana
AU  - Schiller, Jürgen
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3522
AB  - Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters, in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration.
PB  - John Wiley and Sons Ltd
T2  - Rapid Communications in Mass Spectrometry
T1  - Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease
VL  - 34
IS  - 4
DO  - 10.1002/rcm.8595
ER  - 

@article{
author = "Miletić Vukajlović, Jadranka and Drakulić, Dunja and Pejić, Snežana and Ilić, Tihomir V. and Stefanović, Aleksandra and Petković, Marijana and Schiller, Jürgen",
year = "2020",
abstract = "Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters, in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration.",
publisher = "John Wiley and Sons Ltd",
journal = "Rapid Communications in Mass Spectrometry",
title = "Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease",
volume = "34",
number = "4",
doi = "10.1002/rcm.8595"
}

Miletić Vukajlović, J., Drakulić, D., Pejić, S., Ilić, T. V., Stefanović, A., Petković, M.,& Schiller, J.. (2020). Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease. in Rapid Communications in Mass Spectrometry
John Wiley and Sons Ltd., 34(4).
https://doi.org/10.1002/rcm.8595

Miletić Vukajlović J, Drakulić D, Pejić S, Ilić TV, Stefanović A, Petković M, Schiller J. Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease. in Rapid Communications in Mass Spectrometry. 2020;34(4).
doi:10.1002/rcm.8595 .

Miletić Vukajlović, Jadranka, Drakulić, Dunja, Pejić, Snežana, Ilić, Tihomir V., Stefanović, Aleksandra, Petković, Marijana, Schiller, Jürgen, "Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease" in Rapid Communications in Mass Spectrometry, 34, no. 4 (2020),
https://doi.org/10.1002/rcm.8595 . .

TY  - THES
AU  - Golubović, Bojana C.
PY  - 2019
UR  - http://nardus.mpn.gov.rs/handle/123456789/11250
UR  - http://eteze.bg.ac.rs/application/showtheses?thesesId=6811
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:19903/bdef:Content/download
UR  - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=2048355426
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3689
AB  - Циљ докторске дисертације био је да се применом популационефармакокинетичке анализе идентификују и квантификују факторифармакокинетичке варијабилности такролимуса и сиролимуса у пацијената сатрансплантираним бубрегом.Сви коришћени подаци, укључујући измерене концентрације лекова, били су деоредовног терапијског и клиничког праћења пацијената. Популациона анализавршена је коришћењем софтвера NONMEM®. Подаци за такролимус за период до6 месеци и период од око годину дана након трансплантације анализирани сунезависно. Према критеријумима за укључивање/искључивање укупно је у групиза рани период након трансплантације било 105 пацијената, док је у групи запериод од око годину дана након трансплантације било 45 пацијената. Развијенимодели валидирани су техникама интерне валидације. Групу за развој модела засиролимус чинили су подаци 25 пацијената, док су подаци 13 пацијенатакоришћени за екстерну валидацију. Додатно, развијени модел за сиролимусвалидиран је и техникама интерне валидације.Као фактори фармакокинетичке варијабилности оралног клиренса (CL/F)такролимуса у првих 6 месеци након трансплантације идентификовани супротекло време од трансплантације, укупна телесна маса, хематокрит, нивоаспартат аминотрансферазе (АST) и укупни протеини плазме. На вредности CL/F упериоду од око годину дана након трансплантације значајно су утицали укупнателесна маса и дневна доза такролимуса. Део варијабилности у CL/F сиролимусаобјашњен је старошћу и функцијом јетре, израженом преко АST. Валидацијаразвијених модела показала је њихову стабилност и адекватну предиктабилност.Примена добијених валидираних модела омогућава израчунавање индивидуалнихвредности CL/F, параметра који је основ за индивидуализацију режима дозирања.
AB  - The aim of the doctoral dissertation was to identify and quantify factors of thepharmacokinetic variability of tacrolimus and sirolimus in patients with a transplantedkidney using the population pharmacokinetic analysis.All data used, including measured drug concentrations, were part of the regulartherapeutic and clinical monitoring of patients. Population analysis was performed usingNONMEM® software. Data for tacrolimus for a period of up to 6 months and a period ofabout a year after transplantation were analyzed independently. According to the criteriafor inclusion / exclusion, in the group for the early period after transplantation were 105patients, while in the group for the period of approximately one year after thetransplantаtion were 45 patients. Developed models are validated by internal validationtechniques. The sirolimus model was developed using data of 25 patients, while data of13 patients were used for external validation. In addition, the developed model forsirolimus was validated by internal validation techniques.The post-transplantation time, total body weight, hematocrit, aspartate aminotransferaselevel (AST) and total plasma proteins have been identified as factors of thepharmacokinetic variability of tacrolimus oral clearance (CL/F) in the first 6 monthsfollowing transplantation. On the other hand, the CL/F in the period of about a yearafter the transplantation were significantly influenced by the total body weight andtacrolimus daily dose. Part of the variability in sirolimus CL/F was explained by the ageand function of the liver, expressed through AST. The validation of the developedmodels has shown their stability and adequate predictability. The application of theobtained validated models allows estimation of individual CL/F, a parameter that is thebasis for dosing regimen individualization
PB  - Универзитет у Београду, Фармацеутски факултет
T2  - Универзитет у Београду
T1  - Популациони приступ фармакокинетичкој анализи такролимуса и сиролимуса у пацијената са трансплантираним бубрегом
UR  - https://hdl.handle.net/21.15107/rcub_nardus_11250
ER  - 

@phdthesis{
author = "Golubović, Bojana C.",
year = "2019",
abstract = "Циљ докторске дисертације био је да се применом популационефармакокинетичке анализе идентификују и квантификују факторифармакокинетичке варијабилности такролимуса и сиролимуса у пацијената сатрансплантираним бубрегом.Сви коришћени подаци, укључујући измерене концентрације лекова, били су деоредовног терапијског и клиничког праћења пацијената. Популациона анализавршена је коришћењем софтвера NONMEM®. Подаци за такролимус за период до6 месеци и период од око годину дана након трансплантације анализирани сунезависно. Према критеријумима за укључивање/искључивање укупно је у групиза рани период након трансплантације било 105 пацијената, док је у групи запериод од око годину дана након трансплантације било 45 пацијената. Развијенимодели валидирани су техникама интерне валидације. Групу за развој модела засиролимус чинили су подаци 25 пацијената, док су подаци 13 пацијенатакоришћени за екстерну валидацију. Додатно, развијени модел за сиролимусвалидиран је и техникама интерне валидације.Као фактори фармакокинетичке варијабилности оралног клиренса (CL/F)такролимуса у првих 6 месеци након трансплантације идентификовани супротекло време од трансплантације, укупна телесна маса, хематокрит, нивоаспартат аминотрансферазе (АST) и укупни протеини плазме. На вредности CL/F упериоду од око годину дана након трансплантације значајно су утицали укупнателесна маса и дневна доза такролимуса. Део варијабилности у CL/F сиролимусаобјашњен је старошћу и функцијом јетре, израженом преко АST. Валидацијаразвијених модела показала је њихову стабилност и адекватну предиктабилност.Примена добијених валидираних модела омогућава израчунавање индивидуалнихвредности CL/F, параметра који је основ за индивидуализацију режима дозирања., The aim of the doctoral dissertation was to identify and quantify factors of thepharmacokinetic variability of tacrolimus and sirolimus in patients with a transplantedkidney using the population pharmacokinetic analysis.All data used, including measured drug concentrations, were part of the regulartherapeutic and clinical monitoring of patients. Population analysis was performed usingNONMEM® software. Data for tacrolimus for a period of up to 6 months and a period ofabout a year after transplantation were analyzed independently. According to the criteriafor inclusion / exclusion, in the group for the early period after transplantation were 105patients, while in the group for the period of approximately one year after thetransplantаtion were 45 patients. Developed models are validated by internal validationtechniques. The sirolimus model was developed using data of 25 patients, while data of13 patients were used for external validation. In addition, the developed model forsirolimus was validated by internal validation techniques.The post-transplantation time, total body weight, hematocrit, aspartate aminotransferaselevel (AST) and total plasma proteins have been identified as factors of thepharmacokinetic variability of tacrolimus oral clearance (CL/F) in the first 6 monthsfollowing transplantation. On the other hand, the CL/F in the period of about a yearafter the transplantation were significantly influenced by the total body weight andtacrolimus daily dose. Part of the variability in sirolimus CL/F was explained by the ageand function of the liver, expressed through AST. The validation of the developedmodels has shown their stability and adequate predictability. The application of theobtained validated models allows estimation of individual CL/F, a parameter that is thebasis for dosing regimen individualization",
publisher = "Универзитет у Београду, Фармацеутски факултет",
journal = "Универзитет у Београду",
title = "Популациони приступ фармакокинетичкој анализи такролимуса и сиролимуса у пацијената са трансплантираним бубрегом",
url = "https://hdl.handle.net/21.15107/rcub_nardus_11250"
}

Golubović, B. C.. (2019). Популациони приступ фармакокинетичкој анализи такролимуса и сиролимуса у пацијената са трансплантираним бубрегом. in Универзитет у Београду
Универзитет у Београду, Фармацеутски факултет..
https://hdl.handle.net/21.15107/rcub_nardus_11250

Golubović BC. Популациони приступ фармакокинетичкој анализи такролимуса и сиролимуса у пацијената са трансплантираним бубрегом. in Универзитет у Београду. 2019;.
https://hdl.handle.net/21.15107/rcub_nardus_11250 .

Golubović, Bojana C., "Популациони приступ фармакокинетичкој анализи такролимуса и сиролимуса у пацијената са трансплантираним бубрегом" in Универзитет у Београду (2019),
https://hdl.handle.net/21.15107/rcub_nardus_11250 .

TY  - JOUR
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
AU  - Miljković, Branislava
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3733
AB  - Objective: Cardiovascular disease (CVD) drugs have been frequently implicated in adverse drug reaction (ADR)-related hospitalizations. Drug-drug interactions (DDIs) are common preventable cause of ADRs, but the impact of DDIs in the CVD population has not been investigated. Hence, the primary aim of the study was to identify DDIs associated with ADRs in CVD patients at hospital admission. The second aim was to develop a simple tool to identify high-risk patients for DDI-related adverse events. Methods: An observational study was conducted on the Cardiology Ward of University Clinical Hospital Center. Data were obtained from medical charts. A clinical panel identified DDIs implicated in ADRs, using LexiInteract database and Drug Interaction Probability Scale. Statistics were performed using PASW 22 (SPSS Inc.). Results: DDIs contributed to hospital admission with a total prevalence of 9.69%. DDI-related ADRs affected mainly cardiac function (heart rate or rhythm, 41.07%); bleeding and effect on blood pressure were equally distributed (17.86%). Non-cardiovascular ADRs were found in 23.21% of DDIs. After admission, 73% of the identified DDIs led to changes in prescription. Prediction ability of calculated DDI adverse event probability scores was rated as good (AUC = 0.80, p < .001). Conclusions: CVD patients are highly exposed to adverse DDIs; about one in ten patients hospitalized with CVD might have a DDI contributing to the hospitalization. Given the high prevalence of CVD, DDI-related harm might be a significant burden worldwide. Identification of patients with high DDI adverse event risk might ease the recognition of DDI-related harm and improve the use of electronic databases in clinical practice.
PB  - Taylor and Francis Ltd
T2  - Current Medical Research and Opinion
T1  - Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items
VL  - 35
IS  - 11
SP  - 1873
EP  - 1883
DO  - 10.1080/03007995.2019.1647021
ER  - 

@article{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Radovanović, Slavica and Stevanović, Predrag and Miljković, Branislava",
year = "2019",
abstract = "Objective: Cardiovascular disease (CVD) drugs have been frequently implicated in adverse drug reaction (ADR)-related hospitalizations. Drug-drug interactions (DDIs) are common preventable cause of ADRs, but the impact of DDIs in the CVD population has not been investigated. Hence, the primary aim of the study was to identify DDIs associated with ADRs in CVD patients at hospital admission. The second aim was to develop a simple tool to identify high-risk patients for DDI-related adverse events. Methods: An observational study was conducted on the Cardiology Ward of University Clinical Hospital Center. Data were obtained from medical charts. A clinical panel identified DDIs implicated in ADRs, using LexiInteract database and Drug Interaction Probability Scale. Statistics were performed using PASW 22 (SPSS Inc.). Results: DDIs contributed to hospital admission with a total prevalence of 9.69%. DDI-related ADRs affected mainly cardiac function (heart rate or rhythm, 41.07%); bleeding and effect on blood pressure were equally distributed (17.86%). Non-cardiovascular ADRs were found in 23.21% of DDIs. After admission, 73% of the identified DDIs led to changes in prescription. Prediction ability of calculated DDI adverse event probability scores was rated as good (AUC = 0.80, p < .001). Conclusions: CVD patients are highly exposed to adverse DDIs; about one in ten patients hospitalized with CVD might have a DDI contributing to the hospitalization. Given the high prevalence of CVD, DDI-related harm might be a significant burden worldwide. Identification of patients with high DDI adverse event risk might ease the recognition of DDI-related harm and improve the use of electronic databases in clinical practice.",
publisher = "Taylor and Francis Ltd",
journal = "Current Medical Research and Opinion",
title = "Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items",
volume = "35",
number = "11",
pages = "1873-1883",
doi = "10.1080/03007995.2019.1647021"
}

Kovačević, M., Vezmar-Kovačević, S., Radovanović, S., Stevanović, P.,& Miljković, B.. (2019). Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. in Current Medical Research and Opinion
Taylor and Francis Ltd., 35(11), 1873-1883.
https://doi.org/10.1080/03007995.2019.1647021

Kovačević M, Vezmar-Kovačević S, Radovanović S, Stevanović P, Miljković B. Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. in Current Medical Research and Opinion. 2019;35(11):1873-1883.
doi:10.1080/03007995.2019.1647021 .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Radovanović, Slavica, Stevanović, Predrag, Miljković, Branislava, "Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items" in Current Medical Research and Opinion, 35, no. 11 (2019):1873-1883,
https://doi.org/10.1080/03007995.2019.1647021 . .

TY  - JOUR
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3340
AB  - Background: Due to wide intra- and inter-individual pharmacokinetic variability and narrow therapeutic index of sirolimus, the therapeutic drug monitoring (TDM) of sirolimus with detailed biochemical and clinical monitoring is necessary for dose individualization in kidney transplant patients. The purpose of the study was to explore and identify factors that contribute to pharmacokinetic variability by developing and validating a population model using routine TDM data and routinely monitored biochemical and clinical parameters. Methods: The data obtained by routine monitoring of 38 patients over a period of one year from the sirolimus treatment initiation, were collected from patients' records. Population analysis was performed using the software NONMEM (R). The validity of the model was tested by the internal and external validation techniques. Results: The pharmacokinetic variability was partially explained with patient's age and liver function. CL/F was found to decrease with age. According to the developed model, sirolimus CL/F decreases by, in average, 37% in patients with aspartate aminotransferase (AST) greater than 37 IU/L. The internal and external validation confirmed the satisfactory prediction of the developed model. Conclusions: The population modeling of routinely monitored data allowed quantification of the age and liver function influence on sirolimus CL/F. According to the final model, patients with compromised liver function expressed via AST values require careful monitoring and dosing adjustments. Proven good predictive performance makes this model a useful tool in everyday clinical practice.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach
VL  - 38
IS  - 3
SP  - 323
EP  - 331
DO  - 10.2478/jomb-2018-0030
ER  - 

@article{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2019",
abstract = "Background: Due to wide intra- and inter-individual pharmacokinetic variability and narrow therapeutic index of sirolimus, the therapeutic drug monitoring (TDM) of sirolimus with detailed biochemical and clinical monitoring is necessary for dose individualization in kidney transplant patients. The purpose of the study was to explore and identify factors that contribute to pharmacokinetic variability by developing and validating a population model using routine TDM data and routinely monitored biochemical and clinical parameters. Methods: The data obtained by routine monitoring of 38 patients over a period of one year from the sirolimus treatment initiation, were collected from patients' records. Population analysis was performed using the software NONMEM (R). The validity of the model was tested by the internal and external validation techniques. Results: The pharmacokinetic variability was partially explained with patient's age and liver function. CL/F was found to decrease with age. According to the developed model, sirolimus CL/F decreases by, in average, 37% in patients with aspartate aminotransferase (AST) greater than 37 IU/L. The internal and external validation confirmed the satisfactory prediction of the developed model. Conclusions: The population modeling of routinely monitored data allowed quantification of the age and liver function influence on sirolimus CL/F. According to the final model, patients with compromised liver function expressed via AST values require careful monitoring and dosing adjustments. Proven good predictive performance makes this model a useful tool in everyday clinical practice.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach",
volume = "38",
number = "3",
pages = "323-331",
doi = "10.2478/jomb-2018-0030"
}

Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2019). Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 323-331.
https://doi.org/10.2478/jomb-2018-0030

Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach. in Journal of Medical Biochemistry. 2019;38(3):323-331.
doi:10.2478/jomb-2018-0030 .

Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach" in Journal of Medical Biochemistry, 38, no. 3 (2019):323-331,
https://doi.org/10.2478/jomb-2018-0030 . .

TY  - JOUR
AU  - Pejčić, Zorica
AU  - Vučićević, Katarina
AU  - Garcia-Arieta, Alfredo
AU  - Miljković, Branislava
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3244
AB  - Aims Generic products can be regarded as therapeutically equivalent and switchable with the reference product. However, switchability between generics is unknown, as direct comparisons between generics are not performed. The aim of this study was to investigate the bioequivalence between generic clopidogrel products by means of adjusted indirect comparisons (AICs). Methods AICs were conducted to assess bioequivalence between 4 generic clopidogrel products that are authorised in Serbia. Generics are considered equivalent to the reference if the 90% confidence intervals (CIs) for the ratios test/reference of the maximum concentration (C-max) and area under the curve up to the last measurable concentration (AUC(0-t)) fall within the acceptance range 80.00-125.00%. However, for AICs between generics, the Canadian acceptance criterion for C-max was employed, where only the point estimate of C-max needs to be within 80.00-125.00%. Results The 90% CIs of the AICs demonstrated bioequivalence within 80.00-125.00% for all AUC(0-t) comparisons. The point estimates of C-max in all AICs were also within this range. Conclusion This study demonstrates that the bioavailability of these 4 generic clopidogrel products authorised in Serbia is very similar. Despite the limited power of AICs, bioequivalence was demonstrated for all 90% CIs of AUC(0-t) and all 90% CIs of C-max comparisons were within or very close to the acceptance range, being able to comply with the acceptance criterion employed in Canada for C-max. Therefore, these 4 generic clopidogrel products authorised in Serbia can be considered switchable with each other in clinical practice based on the adjusted indirect comparisons.
PB  - Wiley, Hoboken
T2  - British Journal of Clinical Pharmacology
T1  - Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia
DO  - 10.1111/bcp.13997
ER  - 

@article{
author = "Pejčić, Zorica and Vučićević, Katarina and Garcia-Arieta, Alfredo and Miljković, Branislava",
year = "2019",
abstract = "Aims Generic products can be regarded as therapeutically equivalent and switchable with the reference product. However, switchability between generics is unknown, as direct comparisons between generics are not performed. The aim of this study was to investigate the bioequivalence between generic clopidogrel products by means of adjusted indirect comparisons (AICs). Methods AICs were conducted to assess bioequivalence between 4 generic clopidogrel products that are authorised in Serbia. Generics are considered equivalent to the reference if the 90% confidence intervals (CIs) for the ratios test/reference of the maximum concentration (C-max) and area under the curve up to the last measurable concentration (AUC(0-t)) fall within the acceptance range 80.00-125.00%. However, for AICs between generics, the Canadian acceptance criterion for C-max was employed, where only the point estimate of C-max needs to be within 80.00-125.00%. Results The 90% CIs of the AICs demonstrated bioequivalence within 80.00-125.00% for all AUC(0-t) comparisons. The point estimates of C-max in all AICs were also within this range. Conclusion This study demonstrates that the bioavailability of these 4 generic clopidogrel products authorised in Serbia is very similar. Despite the limited power of AICs, bioequivalence was demonstrated for all 90% CIs of AUC(0-t) and all 90% CIs of C-max comparisons were within or very close to the acceptance range, being able to comply with the acceptance criterion employed in Canada for C-max. Therefore, these 4 generic clopidogrel products authorised in Serbia can be considered switchable with each other in clinical practice based on the adjusted indirect comparisons.",
publisher = "Wiley, Hoboken",
journal = "British Journal of Clinical Pharmacology",
title = "Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia",
doi = "10.1111/bcp.13997"
}

Pejčić, Z., Vučićević, K., Garcia-Arieta, A.,& Miljković, B.. (2019). Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia. in British Journal of Clinical Pharmacology
Wiley, Hoboken..
https://doi.org/10.1111/bcp.13997

Pejčić Z, Vučićević K, Garcia-Arieta A, Miljković B. Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia. in British Journal of Clinical Pharmacology. 2019;.
doi:10.1111/bcp.13997 .

Pejčić, Zorica, Vučićević, Katarina, Garcia-Arieta, Alfredo, Miljković, Branislava, "Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia" in British Journal of Clinical Pharmacology (2019),
https://doi.org/10.1111/bcp.13997 . .

TY  - JOUR
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3228
AB  - Background: Asthma self-management is aimed to improve the quality and effectiveness of asthma care by supporting the patients to manage their illness by themselves. Objective: The aim of the study was to evaluate the impact of pharmacist-delivered counselling on patients knowledge and beliefs about the medicines, adherence level, and asthma control. Methods: A prospective intervention study was conducted in community pharmacies. A total of 90 patients completed the study. Four questionnaires were used: (1) Beliefs about medicines questionnaire (BMQ), (2) Knowledge of asthma and asthma medicine (KAM), (3) Asthma control test (ACT), and (4) 8-item Morisky medication adherence scale questionnaire (MMAS-8). Questionnaires were completed at baseline and 3 months later. Results: Low level of adherence and poor asthma control were determined initially. Better asthma control was significantly associated with higher adherence level, lower concerns regarding the medication use, and knowledge of triggers. Statistically significant improvement was found after 3 months in patients knowledge of asthma and its medications, their attitude towards medications (decrease in harm, overuse and concern; increase in necessity score), asthma control score (increased from 19 to 20, p  lt  0.05) and level of adherence (MMAS-8 score decreased from 3 to 2 p  lt  0.05). Better asthma control was achieved in 60% of patients. Sixteen patients (18%) were transferred from poor to well-controlled asthma, implying no need for patients' referral to the doctor and no additional cost for the health system. Conclusions: Improved disease control could be a result of enhanced knowledge and understanding of the disease-medication relationship, improved inhalation technique, and support on patients' adherence. Acquired knowledge and skills, as well as improved attitude, empowered patients to take a more active part in asthma management. Education in further patients' follow-up should consider topics tailored to the patients' characteristics, needs, and prior counselling schedule with issues discussed.
PB  - Elsevier Science Inc, New York
T2  - Respiratory Medicine
T1  - Impact of community pharmacists' interventions on asthma self-management care
VL  - 14
IS  - 6
SP  - 603
EP  - 611
DO  - 10.1016/j.sapharm.2017.07.007
ER  - 

@article{
author = "Kovačević, Milena and Ćulafić, Milica and Jovanović, Marija and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2018",
abstract = "Background: Asthma self-management is aimed to improve the quality and effectiveness of asthma care by supporting the patients to manage their illness by themselves. Objective: The aim of the study was to evaluate the impact of pharmacist-delivered counselling on patients knowledge and beliefs about the medicines, adherence level, and asthma control. Methods: A prospective intervention study was conducted in community pharmacies. A total of 90 patients completed the study. Four questionnaires were used: (1) Beliefs about medicines questionnaire (BMQ), (2) Knowledge of asthma and asthma medicine (KAM), (3) Asthma control test (ACT), and (4) 8-item Morisky medication adherence scale questionnaire (MMAS-8). Questionnaires were completed at baseline and 3 months later. Results: Low level of adherence and poor asthma control were determined initially. Better asthma control was significantly associated with higher adherence level, lower concerns regarding the medication use, and knowledge of triggers. Statistically significant improvement was found after 3 months in patients knowledge of asthma and its medications, their attitude towards medications (decrease in harm, overuse and concern; increase in necessity score), asthma control score (increased from 19 to 20, p  lt  0.05) and level of adherence (MMAS-8 score decreased from 3 to 2 p  lt  0.05). Better asthma control was achieved in 60% of patients. Sixteen patients (18%) were transferred from poor to well-controlled asthma, implying no need for patients' referral to the doctor and no additional cost for the health system. Conclusions: Improved disease control could be a result of enhanced knowledge and understanding of the disease-medication relationship, improved inhalation technique, and support on patients' adherence. Acquired knowledge and skills, as well as improved attitude, empowered patients to take a more active part in asthma management. Education in further patients' follow-up should consider topics tailored to the patients' characteristics, needs, and prior counselling schedule with issues discussed.",
publisher = "Elsevier Science Inc, New York",
journal = "Respiratory Medicine",
title = "Impact of community pharmacists' interventions on asthma self-management care",
volume = "14",
number = "6",
pages = "603-611",
doi = "10.1016/j.sapharm.2017.07.007"
}

Kovačević, M., Ćulafić, M., Jovanović, M., Vučićević, K., Vezmar-Kovačević, S.,& Miljković, B.. (2018). Impact of community pharmacists' interventions on asthma self-management care. in Respiratory Medicine
Elsevier Science Inc, New York., 14(6), 603-611.
https://doi.org/10.1016/j.sapharm.2017.07.007

Kovačević M, Ćulafić M, Jovanović M, Vučićević K, Vezmar-Kovačević S, Miljković B. Impact of community pharmacists' interventions on asthma self-management care. in Respiratory Medicine. 2018;14(6):603-611.
doi:10.1016/j.sapharm.2017.07.007 .

Kovačević, Milena, Ćulafić, Milica, Jovanović, Marija, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Impact of community pharmacists' interventions on asthma self-management care" in Respiratory Medicine, 14, no. 6 (2018):603-611,
https://doi.org/10.1016/j.sapharm.2017.07.007 . .

TY  - JOUR
AU  - Ilić, Violeta
AU  - Bogićević, Dragana
AU  - Miljković, Branislava
AU  - Vezmar-Kovačević, Sandra
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3049
AB  - Background and Aim: Adverse effects are common in children treated with antiepileptic medications and may affect parental beliefs about treatment. The aim of the study was to investigate the relationship between adverse effects and parental beliefs about antiepileptic drugs used for the treatment of their children. Methods: The study was performed at the University Children's Hospital, Belgrade, Serbia from 2013-2015. Parents of children treated with valproic acid, carbamazepine or lamotrigine, were eligible. They were asked to fill in the Beliefs about Medications Questionnaire (BMQ) and The Liverpool Adverse Events Profile (LAEP). Results: Parents of 127 children (average age 9.88 +/- 4.16 years) of whom 111 had epilepsy (67 generalized, 44 focal) and 16 with febrile seizures participated in the study. Nervousness and/or agitation, weight gain, restlessness, headache, difficulty in concentrating, feeling of aggression and upset stomach were most frequent adverse effects, reported in 37% of the population. BMQ-specific necessity scores significantly correlated with parental education; parents with elementary school showed lower scores than those with higher education. The presence of difficulty in concentrating of their child was associated with higher BMQ concern scores (20.73 +/- 4.25 vs. 18.99 +/- 3.60, p = 0.043) as well as necessity scores (18.42 +/- 3.31 vs. 16.40 +/- 2.73, p = 0.017). Higher scores of BMQ-general overuse were reported in the presence of a headache (8.79 +/- 2.81 vs. 7.64 +/- 2.72, p = 0.027). Conclusions: The main finding of our study is that parental beliefs about antiepileptic drugs were associated with the presence of adverse effects. Understanding this relationship could allow physicians and pharmacists to structure better educational programs for parents of children treated with antiepileptic drugs. Education should be more focused towards understanding the adverse effects of antiepileptics which could alleviate parental concerns and strengthen their beliefs about the necessity of medication use in their children.
PB  - MDPI, Basel
T2  - Medicina-Lithuania
T1  - Association between Adverse Effects and Parental Beliefs about Antiepileptic Medicines
VL  - 54
IS  - 4
DO  - 10.3390/medicina54040060
ER  - 

@article{
author = "Ilić, Violeta and Bogićević, Dragana and Miljković, Branislava and Vezmar-Kovačević, Sandra",
year = "2018",
abstract = "Background and Aim: Adverse effects are common in children treated with antiepileptic medications and may affect parental beliefs about treatment. The aim of the study was to investigate the relationship between adverse effects and parental beliefs about antiepileptic drugs used for the treatment of their children. Methods: The study was performed at the University Children's Hospital, Belgrade, Serbia from 2013-2015. Parents of children treated with valproic acid, carbamazepine or lamotrigine, were eligible. They were asked to fill in the Beliefs about Medications Questionnaire (BMQ) and The Liverpool Adverse Events Profile (LAEP). Results: Parents of 127 children (average age 9.88 +/- 4.16 years) of whom 111 had epilepsy (67 generalized, 44 focal) and 16 with febrile seizures participated in the study. Nervousness and/or agitation, weight gain, restlessness, headache, difficulty in concentrating, feeling of aggression and upset stomach were most frequent adverse effects, reported in 37% of the population. BMQ-specific necessity scores significantly correlated with parental education; parents with elementary school showed lower scores than those with higher education. The presence of difficulty in concentrating of their child was associated with higher BMQ concern scores (20.73 +/- 4.25 vs. 18.99 +/- 3.60, p = 0.043) as well as necessity scores (18.42 +/- 3.31 vs. 16.40 +/- 2.73, p = 0.017). Higher scores of BMQ-general overuse were reported in the presence of a headache (8.79 +/- 2.81 vs. 7.64 +/- 2.72, p = 0.027). Conclusions: The main finding of our study is that parental beliefs about antiepileptic drugs were associated with the presence of adverse effects. Understanding this relationship could allow physicians and pharmacists to structure better educational programs for parents of children treated with antiepileptic drugs. Education should be more focused towards understanding the adverse effects of antiepileptics which could alleviate parental concerns and strengthen their beliefs about the necessity of medication use in their children.",
publisher = "MDPI, Basel",
journal = "Medicina-Lithuania",
title = "Association between Adverse Effects and Parental Beliefs about Antiepileptic Medicines",
volume = "54",
number = "4",
doi = "10.3390/medicina54040060"
}

Ilić, V., Bogićević, D., Miljković, B.,& Vezmar-Kovačević, S.. (2018). Association between Adverse Effects and Parental Beliefs about Antiepileptic Medicines. in Medicina-Lithuania
MDPI, Basel., 54(4).
https://doi.org/10.3390/medicina54040060

Ilić V, Bogićević D, Miljković B, Vezmar-Kovačević S. Association between Adverse Effects and Parental Beliefs about Antiepileptic Medicines. in Medicina-Lithuania. 2018;54(4).
doi:10.3390/medicina54040060 .

Ilić, Violeta, Bogićević, Dragana, Miljković, Branislava, Vezmar-Kovačević, Sandra, "Association between Adverse Effects and Parental Beliefs about Antiepileptic Medicines" in Medicina-Lithuania, 54, no. 4 (2018),
https://doi.org/10.3390/medicina54040060 . .

TY  - JOUR
AU  - Miletić, Jadranka
AU  - Drakulić, Dunja
AU  - Pejić, Snežana
AU  - Petković, Marijana
AU  - Ilić, Tihomir V.
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Prostran, Milica
AU  - Stojanov, Marina
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3163
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3420
AB  - Background: Biomarkers of oxidative stress are relevant in the evaluation of the disease status and prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation products (malondialdehyde and 4-hydroxynonenal) are being extensively evaluated regarding their relationship with clinical presentation and disease severity.Aim of the study: The aim of this study was to evaluate the levels of the above-mentioned parameters in plasma of 39 men and 17 women with Parkinson's disease, originated from the Republic of Serbia and their relation to clinicopathological characteristics (gender, age at examination, duration of the disease, and Hoehn and Yahr score) and oxidative status.Results: The incidence of disease was 2:1 towards males. The investigated oxidative parameters were gender and Hoehn and Yahr related. Significant association of higher Hoehn and Yahr scores was observed for malondialdehyde (p = 0.01) and prooxidant-antioxidant balance (p = 0.02). Relation between oxidant-antioxidant status was further supported by observed positive correlation between 4-hydroxynonenal (p = 0.04) and prooxidant-antioxidant balance (p = 0.03). Finally, the multivariate analysis indicated that prooxidant-antioxidant balance and malondialdehyde were partially determined by gender (10.6% and 7.6%) and Hoehn and Yahr scores (13.6% and 18.8%), while Hoehn and Yahr scores contributed to the variance of advanced oxidation protein products with 13.2%.Conclusion: Our results indicate the higher level of oxidative stress (oxidant-antioxidant imbalance) and possible relation of several markers with gender and disease stage in patients with Parkinson's disease. The analyzed markers could be used to specify the severity of oxidative stress; however, their potential value should be analyzed in further studies.
PB  - Taylor & Francis Ltd, Abingdon
T2  - International Journal of Neuroscience
T1  - Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease
VL  - 128
IS  - 7
SP  - 600
EP  - 607
DO  - 10.1080/00207454.2017.1403916
ER  - 

@article{
author = "Miletić, Jadranka and Drakulić, Dunja and Pejić, Snežana and Petković, Marijana and Ilić, Tihomir V. and Miljković, Milica and Stefanović, Aleksandra and Prostran, Milica and Stojanov, Marina",
year = "2018",
abstract = "Background: Biomarkers of oxidative stress are relevant in the evaluation of the disease status and prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation products (malondialdehyde and 4-hydroxynonenal) are being extensively evaluated regarding their relationship with clinical presentation and disease severity.Aim of the study: The aim of this study was to evaluate the levels of the above-mentioned parameters in plasma of 39 men and 17 women with Parkinson's disease, originated from the Republic of Serbia and their relation to clinicopathological characteristics (gender, age at examination, duration of the disease, and Hoehn and Yahr score) and oxidative status.Results: The incidence of disease was 2:1 towards males. The investigated oxidative parameters were gender and Hoehn and Yahr related. Significant association of higher Hoehn and Yahr scores was observed for malondialdehyde (p = 0.01) and prooxidant-antioxidant balance (p = 0.02). Relation between oxidant-antioxidant status was further supported by observed positive correlation between 4-hydroxynonenal (p = 0.04) and prooxidant-antioxidant balance (p = 0.03). Finally, the multivariate analysis indicated that prooxidant-antioxidant balance and malondialdehyde were partially determined by gender (10.6% and 7.6%) and Hoehn and Yahr scores (13.6% and 18.8%), while Hoehn and Yahr scores contributed to the variance of advanced oxidation protein products with 13.2%.Conclusion: Our results indicate the higher level of oxidative stress (oxidant-antioxidant imbalance) and possible relation of several markers with gender and disease stage in patients with Parkinson's disease. The analyzed markers could be used to specify the severity of oxidative stress; however, their potential value should be analyzed in further studies.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "International Journal of Neuroscience",
title = "Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease",
volume = "128",
number = "7",
pages = "600-607",
doi = "10.1080/00207454.2017.1403916"
}

Miletić, J., Drakulić, D., Pejić, S., Petković, M., Ilić, T. V., Miljković, M., Stefanović, A., Prostran, M.,& Stojanov, M.. (2018). Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease. in International Journal of Neuroscience
Taylor & Francis Ltd, Abingdon., 128(7), 600-607.
https://doi.org/10.1080/00207454.2017.1403916

Miletić J, Drakulić D, Pejić S, Petković M, Ilić TV, Miljković M, Stefanović A, Prostran M, Stojanov M. Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease. in International Journal of Neuroscience. 2018;128(7):600-607.
doi:10.1080/00207454.2017.1403916 .

Miletić, Jadranka, Drakulić, Dunja, Pejić, Snežana, Petković, Marijana, Ilić, Tihomir V., Miljković, Milica, Stefanović, Aleksandra, Prostran, Milica, Stojanov, Marina, "Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease" in International Journal of Neuroscience, 128, no. 7 (2018):600-607,
https://doi.org/10.1080/00207454.2017.1403916 . .

TY  - JOUR
AU  - Miletić, Jadranka
AU  - Drakulić, Dunja
AU  - Pejić, Snežana
AU  - Petković, Marijana
AU  - Ilić, Tihomir V.
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Prostran, Milica
AU  - Stojanov, Marina
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3163
AB  - Background: Biomarkers of oxidative stress are relevant in the evaluation of the disease status and prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation products (malondialdehyde and 4-hydroxynonenal) are being extensively evaluated regarding their relationship with clinical presentation and disease severity.Aim of the study: The aim of this study was to evaluate the levels of the above-mentioned parameters in plasma of 39 men and 17 women with Parkinson's disease, originated from the Republic of Serbia and their relation to clinicopathological characteristics (gender, age at examination, duration of the disease, and Hoehn and Yahr score) and oxidative status.Results: The incidence of disease was 2:1 towards males. The investigated oxidative parameters were gender and Hoehn and Yahr related. Significant association of higher Hoehn and Yahr scores was observed for malondialdehyde (p = 0.01) and prooxidant-antioxidant balance (p = 0.02). Relation between oxidant-antioxidant status was further supported by observed positive correlation between 4-hydroxynonenal (p = 0.04) and prooxidant-antioxidant balance (p = 0.03). Finally, the multivariate analysis indicated that prooxidant-antioxidant balance and malondialdehyde were partially determined by gender (10.6% and 7.6%) and Hoehn and Yahr scores (13.6% and 18.8%), while Hoehn and Yahr scores contributed to the variance of advanced oxidation protein products with 13.2%.Conclusion: Our results indicate the higher level of oxidative stress (oxidant-antioxidant imbalance) and possible relation of several markers with gender and disease stage in patients with Parkinson's disease. The analyzed markers could be used to specify the severity of oxidative stress; however, their potential value should be analyzed in further studies.
PB  - Taylor & Francis Ltd, Abingdon
T2  - International Journal of Neuroscience
T1  - Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease
VL  - 128
IS  - 7
SP  - 600
EP  - 607
DO  - 10.1080/00207454.2017.1403916
ER  - 

@article{
author = "Miletić, Jadranka and Drakulić, Dunja and Pejić, Snežana and Petković, Marijana and Ilić, Tihomir V. and Miljković, Milica and Stefanović, Aleksandra and Prostran, Milica and Stojanov, Marina",
year = "2018",
abstract = "Background: Biomarkers of oxidative stress are relevant in the evaluation of the disease status and prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation products (malondialdehyde and 4-hydroxynonenal) are being extensively evaluated regarding their relationship with clinical presentation and disease severity.Aim of the study: The aim of this study was to evaluate the levels of the above-mentioned parameters in plasma of 39 men and 17 women with Parkinson's disease, originated from the Republic of Serbia and their relation to clinicopathological characteristics (gender, age at examination, duration of the disease, and Hoehn and Yahr score) and oxidative status.Results: The incidence of disease was 2:1 towards males. The investigated oxidative parameters were gender and Hoehn and Yahr related. Significant association of higher Hoehn and Yahr scores was observed for malondialdehyde (p = 0.01) and prooxidant-antioxidant balance (p = 0.02). Relation between oxidant-antioxidant status was further supported by observed positive correlation between 4-hydroxynonenal (p = 0.04) and prooxidant-antioxidant balance (p = 0.03). Finally, the multivariate analysis indicated that prooxidant-antioxidant balance and malondialdehyde were partially determined by gender (10.6% and 7.6%) and Hoehn and Yahr scores (13.6% and 18.8%), while Hoehn and Yahr scores contributed to the variance of advanced oxidation protein products with 13.2%.Conclusion: Our results indicate the higher level of oxidative stress (oxidant-antioxidant imbalance) and possible relation of several markers with gender and disease stage in patients with Parkinson's disease. The analyzed markers could be used to specify the severity of oxidative stress; however, their potential value should be analyzed in further studies.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "International Journal of Neuroscience",
title = "Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease",
volume = "128",
number = "7",
pages = "600-607",
doi = "10.1080/00207454.2017.1403916"
}

Miletić, J., Drakulić, D., Pejić, S., Petković, M., Ilić, T. V., Miljković, M., Stefanović, A., Prostran, M.,& Stojanov, M.. (2018). Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease. in International Journal of Neuroscience
Taylor & Francis Ltd, Abingdon., 128(7), 600-607.
https://doi.org/10.1080/00207454.2017.1403916

Miletić J, Drakulić D, Pejić S, Petković M, Ilić TV, Miljković M, Stefanović A, Prostran M, Stojanov M. Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease. in International Journal of Neuroscience. 2018;128(7):600-607.
doi:10.1080/00207454.2017.1403916 .

Miletić, Jadranka, Drakulić, Dunja, Pejić, Snežana, Petković, Marijana, Ilić, Tihomir V., Miljković, Milica, Stefanović, Aleksandra, Prostran, Milica, Stojanov, Marina, "Prooxidant-antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson's disease" in International Journal of Neuroscience, 128, no. 7 (2018):600-607,
https://doi.org/10.1080/00207454.2017.1403916 . .

TY  - JOUR
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Golubović, Bojana
AU  - Jovanović, Marija
AU  - de Gier, Johan J.
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2985
AB  - Objective: To evaluate elderly polypharmacy patients' needs and concerns regarding medication through the Structured Patient-Pharmacist Consultation (SPPC). Methods: Older patients on chronic treatment with > 5 medications were asked to fill in the SPPC form at home. A consultation with the community pharmacist, structured according to patient's answers, followed within 2-4 weeks. Logistic regression associated patients' individual treatment with care issues and consultation outcomes. Results: Out of 440 patients, 39.5% experienced problems, and 46.1% had concerns about medication use. 122 patients reported reasons for discontinuing treatment. The main outcome of the consultation was a better understanding of medication use (75.5%). Side effects and/or non-adherence were identified in 50% of patients, and 26.6% were referred to the doctor. Atrial fibrillation, COPD, anticoagulants, benzodiazepines, and beta agonists/corticosteroids were associated with problems during medication use. Patients with diabetes improved their understanding of medication use significantly. Conclusion: Patients on benzodiazepines, anticoagulants, and beta agonists/corticosteroids, with atrial fibrillation and/or COPD, may have a higher potential for non-adherence. Counseling patients based on the SPPC model may be particularly useful for patients with diabetes.
PB  - Elsevier Ireland Ltd, Clare
T2  - Patient Education and Counseling
T1  - Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model
VL  - 100
IS  - 9
SP  - 1714
EP  - 1719
DO  - 10.1016/j.pec.2017.05.001
ER  - 

@article{
author = "Vezmar-Kovačević, Sandra and Miljković, Branislava and Vučićević, Katarina and Ćulafić, Milica and Kovačević, Milena and Golubović, Bojana and Jovanović, Marija and de Gier, Johan J.",
year = "2017",
abstract = "Objective: To evaluate elderly polypharmacy patients' needs and concerns regarding medication through the Structured Patient-Pharmacist Consultation (SPPC). Methods: Older patients on chronic treatment with > 5 medications were asked to fill in the SPPC form at home. A consultation with the community pharmacist, structured according to patient's answers, followed within 2-4 weeks. Logistic regression associated patients' individual treatment with care issues and consultation outcomes. Results: Out of 440 patients, 39.5% experienced problems, and 46.1% had concerns about medication use. 122 patients reported reasons for discontinuing treatment. The main outcome of the consultation was a better understanding of medication use (75.5%). Side effects and/or non-adherence were identified in 50% of patients, and 26.6% were referred to the doctor. Atrial fibrillation, COPD, anticoagulants, benzodiazepines, and beta agonists/corticosteroids were associated with problems during medication use. Patients with diabetes improved their understanding of medication use significantly. Conclusion: Patients on benzodiazepines, anticoagulants, and beta agonists/corticosteroids, with atrial fibrillation and/or COPD, may have a higher potential for non-adherence. Counseling patients based on the SPPC model may be particularly useful for patients with diabetes.",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Patient Education and Counseling",
title = "Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model",
volume = "100",
number = "9",
pages = "1714-1719",
doi = "10.1016/j.pec.2017.05.001"
}

Vezmar-Kovačević, S., Miljković, B., Vučićević, K., Ćulafić, M., Kovačević, M., Golubović, B., Jovanović, M.,& de Gier, J. J.. (2017). Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model. in Patient Education and Counseling
Elsevier Ireland Ltd, Clare., 100(9), 1714-1719.
https://doi.org/10.1016/j.pec.2017.05.001

Vezmar-Kovačević S, Miljković B, Vučićević K, Ćulafić M, Kovačević M, Golubović B, Jovanović M, de Gier JJ. Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model. in Patient Education and Counseling. 2017;100(9):1714-1719.
doi:10.1016/j.pec.2017.05.001 .

Vezmar-Kovačević, Sandra, Miljković, Branislava, Vučićević, Katarina, Ćulafić, Milica, Kovačević, Milena, Golubović, Bojana, Jovanović, Marija, de Gier, Johan J., "Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model" in Patient Education and Counseling, 100, no. 9 (2017):1714-1719,
https://doi.org/10.1016/j.pec.2017.05.001 . .

TY  - JOUR
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Radovanović, Slavica
AU  - Stevanović, Predrag
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2874
AB  - Aim: The aim was to describe the type and prevalence of potentially relevant drug-drug interactions (pDDIs) in a population of patients admitted for cardiovascular diseases (CVD), and management strategies for reducing the occurrence of pDDIs. Methods: A retrospective cross-sectional study was performed on Cardiology ward of University Clinical Hospital Center in Belgrade, Serbia. A total of 527 patients, with more than one prescription during hospital stay, were enrolled in this study. Data were obtained from medical records. LexiInteract was used as the screening tool. Results: At least one potentially relevant pDDI was identified in 83.9% of patients. Occurrence was significantly more prevalent in patients with higher number of drugs, multimorbidity, longer length of stay, arrhythmia, heart failure, infectious and respiratory disease. About 13% of pDDIs exposures were accompanied with concurrent renal or liver disease, as an additional risk for DDI manifestation. Among CVD, patients with a history of myocardial infarction possessed the highest additional risk. The most common potential clinical outcome was the effect on cardiovascular system 48.5%, renal function and/or potassium 22.3%, bleeding 9.5%, impaired glucose control 6.8% and digoxin toxicity 4.6%. Main management strategies to avoid X or D class included using paracetamol instead of NSAID or alternative NSAID (38%), alternative antibiotic or antifungal (20.4%), H-2 receptor antagonist instead of PPI (8.3%), avoiding therapeutic duplication (7.3%), and alternative HMG-CoA reductase inhibitor (7%). Heart rate, blood pressure, electrolytes/potassium and blood glucose could have been employed in monitoring for potential consequence of 72.2% C class pDDIs. Conclusions: Use of drug interaction screening tools can be beneficial risk mitigation strategy for potentially relevant pDDIs in CVD patients. DDI screening software could be linked to the patient's laboratory results or clinical data regarding renal or liver function, as an approach to reinforce DDIs alert quality.
PB  - Wiley, Hoboken
T2  - International Journal of Clinical Practice
T1  - The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study
VL  - 71
IS  - 10
DO  - 10.1111/ijcp.13005
ER  - 

@article{
author = "Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Radovanović, Slavica and Stevanović, Predrag",
year = "2017",
abstract = "Aim: The aim was to describe the type and prevalence of potentially relevant drug-drug interactions (pDDIs) in a population of patients admitted for cardiovascular diseases (CVD), and management strategies for reducing the occurrence of pDDIs. Methods: A retrospective cross-sectional study was performed on Cardiology ward of University Clinical Hospital Center in Belgrade, Serbia. A total of 527 patients, with more than one prescription during hospital stay, were enrolled in this study. Data were obtained from medical records. LexiInteract was used as the screening tool. Results: At least one potentially relevant pDDI was identified in 83.9% of patients. Occurrence was significantly more prevalent in patients with higher number of drugs, multimorbidity, longer length of stay, arrhythmia, heart failure, infectious and respiratory disease. About 13% of pDDIs exposures were accompanied with concurrent renal or liver disease, as an additional risk for DDI manifestation. Among CVD, patients with a history of myocardial infarction possessed the highest additional risk. The most common potential clinical outcome was the effect on cardiovascular system 48.5%, renal function and/or potassium 22.3%, bleeding 9.5%, impaired glucose control 6.8% and digoxin toxicity 4.6%. Main management strategies to avoid X or D class included using paracetamol instead of NSAID or alternative NSAID (38%), alternative antibiotic or antifungal (20.4%), H-2 receptor antagonist instead of PPI (8.3%), avoiding therapeutic duplication (7.3%), and alternative HMG-CoA reductase inhibitor (7%). Heart rate, blood pressure, electrolytes/potassium and blood glucose could have been employed in monitoring for potential consequence of 72.2% C class pDDIs. Conclusions: Use of drug interaction screening tools can be beneficial risk mitigation strategy for potentially relevant pDDIs in CVD patients. DDI screening software could be linked to the patient's laboratory results or clinical data regarding renal or liver function, as an approach to reinforce DDIs alert quality.",
publisher = "Wiley, Hoboken",
journal = "International Journal of Clinical Practice",
title = "The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study",
volume = "71",
number = "10",
doi = "10.1111/ijcp.13005"
}

Kovačević, M., Vezmar-Kovačević, S., Miljković, B., Radovanović, S.,& Stevanović, P.. (2017). The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study. in International Journal of Clinical Practice
Wiley, Hoboken., 71(10).
https://doi.org/10.1111/ijcp.13005

Kovačević M, Vezmar-Kovačević S, Miljković B, Radovanović S, Stevanović P. The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study. in International Journal of Clinical Practice. 2017;71(10).
doi:10.1111/ijcp.13005 .

Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Radovanović, Slavica, Stevanović, Predrag, "The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study" in International Journal of Clinical Practice, 71, no. 10 (2017),
https://doi.org/10.1111/ijcp.13005 . .

TY  - JOUR
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Golubović, Bojana
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - de Gier, Johan J.
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2811
AB  - Aims and Objectives Targeting older patients with predictive factors for drug-related problems (DRPs) could make clinical medication reviews more cost-effective. The aim of this study was to identify the number, type, and potential predictive factors for DRPs in older polypharmacy patients. Methods Community pharmacists performed clinical medication reviews and documented DRPs, types of interventions, and their implementation in older patients. Results Three hundred eighty-eight medication reviews were analyzed, 964 DRPs (average 2.51.9), and 1022 interventions (average 2.6 +/- 2.0) were identified. The overall implementation rate of interventions was 70.1%, the highest was observed in interventions aiming to resolve the lack of therapy monitoring (86.8%). Patients with 12 medications had an increased risk of 5 DRPs (P  lt  .001). Asthma was associated with lack of adherence (P = .002), lack of aspirin, statins, and proton pump inhibitors use with additional therapy needed (P = .002-.004). Predictive factors for drug interactions were antihypertensive medications and/or medications with narrow therapeutic index (P  lt  .05). Lack of efficacy was associated with diabetes (P = .006). Nonsteroidal anti-inflammatory drugs were risk factors for inappropriate drug selection (P = .002). Lack of monitoring was associated with hypertension (P = .013), whereas benzodiazepines (P  lt  .001) and aspirin (P = .021) were overused. Conclusion Patients with asthma, hypertension, and diabetes and lack of statin, antithrombotic agent, and/or proton pump inhibitor use were associated with higher risks for DRPs.
PB  - Wiley, Hoboken
T2  - Journal of Evaluation in Clinical Practice
T1  - Evaluation of drug-related problems in older polypharmacy primary care patients
VL  - 23
IS  - 4
SP  - 860
EP  - 865
DO  - 10.1111/jep.12737
ER  - 

@article{
author = "Vezmar-Kovačević, Sandra and Miljković, Branislava and Ćulafić, Milica and Kovačević, Milena and Golubović, Bojana and Jovanović, Marija and Vučićević, Katarina and de Gier, Johan J.",
year = "2017",
abstract = "Aims and Objectives Targeting older patients with predictive factors for drug-related problems (DRPs) could make clinical medication reviews more cost-effective. The aim of this study was to identify the number, type, and potential predictive factors for DRPs in older polypharmacy patients. Methods Community pharmacists performed clinical medication reviews and documented DRPs, types of interventions, and their implementation in older patients. Results Three hundred eighty-eight medication reviews were analyzed, 964 DRPs (average 2.51.9), and 1022 interventions (average 2.6 +/- 2.0) were identified. The overall implementation rate of interventions was 70.1%, the highest was observed in interventions aiming to resolve the lack of therapy monitoring (86.8%). Patients with 12 medications had an increased risk of 5 DRPs (P  lt  .001). Asthma was associated with lack of adherence (P = .002), lack of aspirin, statins, and proton pump inhibitors use with additional therapy needed (P = .002-.004). Predictive factors for drug interactions were antihypertensive medications and/or medications with narrow therapeutic index (P  lt  .05). Lack of efficacy was associated with diabetes (P = .006). Nonsteroidal anti-inflammatory drugs were risk factors for inappropriate drug selection (P = .002). Lack of monitoring was associated with hypertension (P = .013), whereas benzodiazepines (P  lt  .001) and aspirin (P = .021) were overused. Conclusion Patients with asthma, hypertension, and diabetes and lack of statin, antithrombotic agent, and/or proton pump inhibitor use were associated with higher risks for DRPs.",
publisher = "Wiley, Hoboken",
journal = "Journal of Evaluation in Clinical Practice",
title = "Evaluation of drug-related problems in older polypharmacy primary care patients",
volume = "23",
number = "4",
pages = "860-865",
doi = "10.1111/jep.12737"
}

Vezmar-Kovačević, S., Miljković, B., Ćulafić, M., Kovačević, M., Golubović, B., Jovanović, M., Vučićević, K.,& de Gier, J. J.. (2017). Evaluation of drug-related problems in older polypharmacy primary care patients. in Journal of Evaluation in Clinical Practice
Wiley, Hoboken., 23(4), 860-865.
https://doi.org/10.1111/jep.12737

Vezmar-Kovačević S, Miljković B, Ćulafić M, Kovačević M, Golubović B, Jovanović M, Vučićević K, de Gier JJ. Evaluation of drug-related problems in older polypharmacy primary care patients. in Journal of Evaluation in Clinical Practice. 2017;23(4):860-865.
doi:10.1111/jep.12737 .

Vezmar-Kovačević, Sandra, Miljković, Branislava, Ćulafić, Milica, Kovačević, Milena, Golubović, Bojana, Jovanović, Marija, Vučićević, Katarina, de Gier, Johan J., "Evaluation of drug-related problems in older polypharmacy primary care patients" in Journal of Evaluation in Clinical Practice, 23, no. 4 (2017):860-865,
https://doi.org/10.1111/jep.12737 . .

TY  - JOUR
AU  - Ljubojević, Gordana
AU  - Miljković, Branislava
AU  - Bucma, Tatjana
AU  - Ćulafić, Milica
AU  - Prostran, Milica
AU  - Vezmar-Kovačević, Sandra
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2801
AB  - Background In the last 30 years, activities of hospital pharmacists have gone through significant changes. Pharmacists are increasingly involved in patient care. Objectives To explore drug-related and logistic problems, interventions, and their outcomes during routine everyday work of hospital pharmacists. Setting Institute for physical medicine and rehabilitation, Banja Luka, Bosnia and Herzegovina. Methods In the period of January 2013-October 2015 a prospective observational study was performed. Medical doctors, nurses, therapists, and patients addressed pharmacists, face-to-face or by telephone, with drug-related problems (DRPs) and/or logistic issues. Main outcome measure Type of DRP or logistic issue, intervention, outcome, initiator and time spent for solving the problem were documented for each consultation. Results Out of 1515 interventions, 48.8% were aimed at solving DRPs. The most common DRPs were the recommendation of a drug or dose and need for additional information about drugs. Drug price and supply were the most prevalent logistic issues. DRPs were more frequently initiated by medical doctors and required more time to solve the problem compared to logistic issues (Mann-Whitney U test, p  lt = 0.001, respectively). The acceptance rate of interventions to solve DRPs (83.7%) was lower compared to logistic issues (95.2%; p  lt = 0.001). Conclusions Hospital pharmacists were faced with an approximately equal number of DRPs and logistic issues during their routine everyday work. The overall acceptance rate of pharmacists' interventions was high, and the results of our study indicate that there is a need for more involvement of hospital pharmacists in Bosnia and Herzegovina in clinical activities. Impact on practice.
PB  - Springer, Dordrecht
T2  - International Journal of Clinical Pharmacy
T1  - Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina
VL  - 39
IS  - 4
SP  - 743
EP  - 749
DO  - 10.1007/s11096-017-0491-x
ER  - 

@article{
author = "Ljubojević, Gordana and Miljković, Branislava and Bucma, Tatjana and Ćulafić, Milica and Prostran, Milica and Vezmar-Kovačević, Sandra",
year = "2017",
abstract = "Background In the last 30 years, activities of hospital pharmacists have gone through significant changes. Pharmacists are increasingly involved in patient care. Objectives To explore drug-related and logistic problems, interventions, and their outcomes during routine everyday work of hospital pharmacists. Setting Institute for physical medicine and rehabilitation, Banja Luka, Bosnia and Herzegovina. Methods In the period of January 2013-October 2015 a prospective observational study was performed. Medical doctors, nurses, therapists, and patients addressed pharmacists, face-to-face or by telephone, with drug-related problems (DRPs) and/or logistic issues. Main outcome measure Type of DRP or logistic issue, intervention, outcome, initiator and time spent for solving the problem were documented for each consultation. Results Out of 1515 interventions, 48.8% were aimed at solving DRPs. The most common DRPs were the recommendation of a drug or dose and need for additional information about drugs. Drug price and supply were the most prevalent logistic issues. DRPs were more frequently initiated by medical doctors and required more time to solve the problem compared to logistic issues (Mann-Whitney U test, p  lt = 0.001, respectively). The acceptance rate of interventions to solve DRPs (83.7%) was lower compared to logistic issues (95.2%; p  lt = 0.001). Conclusions Hospital pharmacists were faced with an approximately equal number of DRPs and logistic issues during their routine everyday work. The overall acceptance rate of pharmacists' interventions was high, and the results of our study indicate that there is a need for more involvement of hospital pharmacists in Bosnia and Herzegovina in clinical activities. Impact on practice.",
publisher = "Springer, Dordrecht",
journal = "International Journal of Clinical Pharmacy",
title = "Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina",
volume = "39",
number = "4",
pages = "743-749",
doi = "10.1007/s11096-017-0491-x"
}

Ljubojević, G., Miljković, B., Bucma, T., Ćulafić, M., Prostran, M.,& Vezmar-Kovačević, S.. (2017). Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina. in International Journal of Clinical Pharmacy
Springer, Dordrecht., 39(4), 743-749.
https://doi.org/10.1007/s11096-017-0491-x

Ljubojević G, Miljković B, Bucma T, Ćulafić M, Prostran M, Vezmar-Kovačević S. Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina. in International Journal of Clinical Pharmacy. 2017;39(4):743-749.
doi:10.1007/s11096-017-0491-x .

Ljubojević, Gordana, Miljković, Branislava, Bucma, Tatjana, Ćulafić, Milica, Prostran, Milica, Vezmar-Kovačević, Sandra, "Problems, interventions, and their outcomes during the routine work of hospital pharmacists in Bosnia and Herzegovina" in International Journal of Clinical Pharmacy, 39, no. 4 (2017):743-749,
https://doi.org/10.1007/s11096-017-0491-x . .

TY  - THES
AU  - Jovanović, Marija
PY  - 2016
UR  - http://eteze.bg.ac.rs/application/showtheses?thesesId=3748
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:12612/bdef:Content/download
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:12755/bdef:Izvestaj/download
UR  - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=48117519
UR  - http://nardus.mpn.gov.rs/123456789/6451
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3391
AB  - Cilj doktorske disertacije je bio da se istraže, otkriju i kvantitativno izraze uticaji faktorakoji doprinose varijabilnosti topiramata (TPM) kod odraslih pacijenata sa epilepsijom.Prvi deo istraživanja je bio fokusiran na razvoj populacionog farmakokinetičkog modelaTPM primenom nelinearnog modelovanja kombinovanih efekata uz programNONMEM®. Podaci su dobijeni od 78 pacijenata koji su bili na mono ili koterapiji TPMi drugim antiepilepticima. Koncentracije TPM u stanju ravnoteže su određene u uzorcimakrvi visoko efikasnom tečnom hromatografijom. Jednoprostorni model sa resorpcijom ieliminacijom prvog reda je korišćen za fitovanje podataka o koncentraciji i vremenu.Razmatrano je ispitivanje uticaja demografskih, biohemijskih i karakteristika terapije naoralni klirens leka (CL/F). Volumen distribucije je procenjen na 0.575 l/kg. Finalni modelukazuje da je povećanje CL/F pod uticajem doze karbamazepina i renalne funkcijenajbolje opisano linearnim i eksponencijalnim modelima. Validacija je potvrdilastabilnost i adekvatne prediktivne karakteristike modela. Dobijeni model pružamogućnost individualizacije režima doziranja TPM u rutinskoj kliničkoj praksi. Udrugom delu istraživanja je ispitan uticaj različitih faktora na nivo bikarbonata i kalijuma.Podaci su dobijeni od 59 pacijenata koji su bili na mono ili koterapiji TPM i drugimantiepilepticima, dok su iz uzorka pre primene doze bile dostupne ravnotežnekoncentracije TPM kod 54. Analiza podataka je vršena SPSS® programom. Primećena jestatistički značajna razlika u vrednosti bikarbonata (p < 0.05) između pacijenata koji suna terapiji TPM duže od 5 godina i onih koji su kraće (ili jednako). Regresiona analiza jepotvrdila da nivo bikarbonata opada linearno sa dužinom terapije. Nije primećenaznačajna veza između doze, nivoa TPM ili starosti pacijenta sa nivoom ispitivanihelektrolita, kao ni između trajanja terapije i nivoa kalijuma. Rezultati ove studijenaglašavaju moguću pojavu nižeg nivoa bikarbonata i kod dužeg trajanja terapije TPM,što ukazuje na značaj praćenja.
AB  - The objective of the doctoral dissertation was to investigate, detect andquantitatively express influence of factors that contribute to topiramate (TPM) variabilityin adult patients with epilepsy. The first part of the research was focused on developingpopulation pharmacokinetic model of TPM using nonlinear mixed effects modellingapproach with NONMEM® program. Data were collected from 78 patients on mono orco-therapy with TPM and other antiepileptic drugs. Steady-state TPM concentrationswere determined in blood samples by high performance liquid chromatography. A onecompartmentmodel with first order absorption and elimination was used to fit theconcentration-time data. The influence of demographic, biochemical parameters andtherapy characteristics on oral clearance (CL/F) was considered for evaluation. Volumeof distribution was estimated at 0.575 l/kg. Final model showed that increase of CL/Fwith carbamazepine dose and renal function was the best described by linear andexponential models. Validation confirmed stability and adequate predictive performanceof the model. This model allows individualization of TPM dosing during routine patientcare. In the second part of the research effect of different factors on bicarbonate andpotassium levels was examined. Data were collected from 59 patients on mono- or cotherapywith TPM and other antiepileptic drugs, while steady-state TPM trough levelswere available from 54. Data analysis was performed by SPSS® program. Significantdifference (p < 0.05) in bicarbonate levels was observed between groups of patientstreated with TPM longer and shorter than (or equal to) 5 years. Regression analysisshowed that bicarbonate levels linearly decreases with therapy duration. No significantassociation was noted between the TPM dose, level or patient age and investigatedelectrolytes, as well as between therapy duration and potassium level. The findings of thisstudy highlight possible occurrence of lower bicarbonate level associated also with longerTPM therapy duration, indicating usefulness of monitoring.
PB  - Универзитет у Београду, Фармацеутски факултет
T2  - Универзитет у Београду
T1  - Identifikacija i kvantifikacija faktora varijabilnosti topiramata kod odraskih pacijenata sa epilepsijom
T1  - Identification and quantification of topiramate variability factors in adult patients with epilepsy
UR  - https://hdl.handle.net/21.15107/rcub_nardus_6451
ER  - 

@phdthesis{
author = "Jovanović, Marija",
year = "2016",
abstract = "Cilj doktorske disertacije je bio da se istraže, otkriju i kvantitativno izraze uticaji faktorakoji doprinose varijabilnosti topiramata (TPM) kod odraslih pacijenata sa epilepsijom.Prvi deo istraživanja je bio fokusiran na razvoj populacionog farmakokinetičkog modelaTPM primenom nelinearnog modelovanja kombinovanih efekata uz programNONMEM®. Podaci su dobijeni od 78 pacijenata koji su bili na mono ili koterapiji TPMi drugim antiepilepticima. Koncentracije TPM u stanju ravnoteže su određene u uzorcimakrvi visoko efikasnom tečnom hromatografijom. Jednoprostorni model sa resorpcijom ieliminacijom prvog reda je korišćen za fitovanje podataka o koncentraciji i vremenu.Razmatrano je ispitivanje uticaja demografskih, biohemijskih i karakteristika terapije naoralni klirens leka (CL/F). Volumen distribucije je procenjen na 0.575 l/kg. Finalni modelukazuje da je povećanje CL/F pod uticajem doze karbamazepina i renalne funkcijenajbolje opisano linearnim i eksponencijalnim modelima. Validacija je potvrdilastabilnost i adekvatne prediktivne karakteristike modela. Dobijeni model pružamogućnost individualizacije režima doziranja TPM u rutinskoj kliničkoj praksi. Udrugom delu istraživanja je ispitan uticaj različitih faktora na nivo bikarbonata i kalijuma.Podaci su dobijeni od 59 pacijenata koji su bili na mono ili koterapiji TPM i drugimantiepilepticima, dok su iz uzorka pre primene doze bile dostupne ravnotežnekoncentracije TPM kod 54. Analiza podataka je vršena SPSS® programom. Primećena jestatistički značajna razlika u vrednosti bikarbonata (p < 0.05) između pacijenata koji suna terapiji TPM duže od 5 godina i onih koji su kraće (ili jednako). Regresiona analiza jepotvrdila da nivo bikarbonata opada linearno sa dužinom terapije. Nije primećenaznačajna veza između doze, nivoa TPM ili starosti pacijenta sa nivoom ispitivanihelektrolita, kao ni između trajanja terapije i nivoa kalijuma. Rezultati ove studijenaglašavaju moguću pojavu nižeg nivoa bikarbonata i kod dužeg trajanja terapije TPM,što ukazuje na značaj praćenja., The objective of the doctoral dissertation was to investigate, detect andquantitatively express influence of factors that contribute to topiramate (TPM) variabilityin adult patients with epilepsy. The first part of the research was focused on developingpopulation pharmacokinetic model of TPM using nonlinear mixed effects modellingapproach with NONMEM® program. Data were collected from 78 patients on mono orco-therapy with TPM and other antiepileptic drugs. Steady-state TPM concentrationswere determined in blood samples by high performance liquid chromatography. A onecompartmentmodel with first order absorption and elimination was used to fit theconcentration-time data. The influence of demographic, biochemical parameters andtherapy characteristics on oral clearance (CL/F) was considered for evaluation. Volumeof distribution was estimated at 0.575 l/kg. Final model showed that increase of CL/Fwith carbamazepine dose and renal function was the best described by linear andexponential models. Validation confirmed stability and adequate predictive performanceof the model. This model allows individualization of TPM dosing during routine patientcare. In the second part of the research effect of different factors on bicarbonate andpotassium levels was examined. Data were collected from 59 patients on mono- or cotherapywith TPM and other antiepileptic drugs, while steady-state TPM trough levelswere available from 54. Data analysis was performed by SPSS® program. Significantdifference (p < 0.05) in bicarbonate levels was observed between groups of patientstreated with TPM longer and shorter than (or equal to) 5 years. Regression analysisshowed that bicarbonate levels linearly decreases with therapy duration. No significantassociation was noted between the TPM dose, level or patient age and investigatedelectrolytes, as well as between therapy duration and potassium level. The findings of thisstudy highlight possible occurrence of lower bicarbonate level associated also with longerTPM therapy duration, indicating usefulness of monitoring.",
publisher = "Универзитет у Београду, Фармацеутски факултет",
journal = "Универзитет у Београду",
title = "Identifikacija i kvantifikacija faktora varijabilnosti topiramata kod odraskih pacijenata sa epilepsijom, Identification and quantification of topiramate variability factors in adult patients with epilepsy",
url = "https://hdl.handle.net/21.15107/rcub_nardus_6451"
}

Jovanović, M.. (2016). Identifikacija i kvantifikacija faktora varijabilnosti topiramata kod odraskih pacijenata sa epilepsijom. in Универзитет у Београду
Универзитет у Београду, Фармацеутски факултет..
https://hdl.handle.net/21.15107/rcub_nardus_6451

Jovanović M. Identifikacija i kvantifikacija faktora varijabilnosti topiramata kod odraskih pacijenata sa epilepsijom. in Универзитет у Београду. 2016;.
https://hdl.handle.net/21.15107/rcub_nardus_6451 .

Jovanović, Marija, "Identifikacija i kvantifikacija faktora varijabilnosti topiramata kod odraskih pacijenata sa epilepsijom" in Универзитет у Београду (2016),
https://hdl.handle.net/21.15107/rcub_nardus_6451 .

TY  - JOUR
AU  - Bajraktarević, Azra
AU  - Mehmedagić, Aida
AU  - Vučićević, Katarina
AU  - Kulić, Mehmed
AU  - Miljković, Branislava
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2667
AB  - Being a narrow therapeutic index drug, digoxin may cause harm if dosed without regular measurements of serum levels. Due to various limitations in its dosing, different challenges still exist in clinical practice. This study aimed to assess digoxin though concentrations after different regimens in adult and elderly patients, and to identify predictor variables for the ratio of given dose and digoxin trough level. This was prospective open-label study. Digoxin was administered per os as 0.125. or 0.25 mg during different continuous and interrupted dosage regimens. Study protocol allowed an additional therapy according to contemporary guidelines. Digoxin concentrations were determined using Abbott AxSYM Digoxin II assay in trough samples (1-3 per patient) after 3-4 weeks stable regimen. In total, 191 concentrations (104 patients) were analyzed. Digoxin weekly dose was in range 0.375-1.75 mg. On average, we observed slightly lower digoxin levels in 1-117 patients. Results showed that in patients receiving digoxin with interrupted dosage regimen post pause digoxin level was statistically significantly lower than pre-pause (p  lt  0.05). Based on multiple linear regression, the ratio of given dose and trough concentration was mainly predicted by clearance creatinine, and to lesser extent by patient's ideal body weight. Interrupted dosing schedule shows greater variability in drug levels comparing to continuous dosing, and it additionally causes difficulties in reaching and maintaining steady trough levels between doses. Hence, individualization of dosing regimen should he carefully guided based on target levels and not solely on clinical signs and symptoms.
PB  - Polskie Towarzystwo Farmaceutyczne, Warsaw
T2  - Acta Poloniae Pharmaceutica - Drug Research
T1  - The posology and trough concentrations of digoxin in adult and elderly patients
VL  - 73
IS  - 5
SP  - 1361
EP  - 1368
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2667
ER  - 

@article{
author = "Bajraktarević, Azra and Mehmedagić, Aida and Vučićević, Katarina and Kulić, Mehmed and Miljković, Branislava",
year = "2016",
abstract = "Being a narrow therapeutic index drug, digoxin may cause harm if dosed without regular measurements of serum levels. Due to various limitations in its dosing, different challenges still exist in clinical practice. This study aimed to assess digoxin though concentrations after different regimens in adult and elderly patients, and to identify predictor variables for the ratio of given dose and digoxin trough level. This was prospective open-label study. Digoxin was administered per os as 0.125. or 0.25 mg during different continuous and interrupted dosage regimens. Study protocol allowed an additional therapy according to contemporary guidelines. Digoxin concentrations were determined using Abbott AxSYM Digoxin II assay in trough samples (1-3 per patient) after 3-4 weeks stable regimen. In total, 191 concentrations (104 patients) were analyzed. Digoxin weekly dose was in range 0.375-1.75 mg. On average, we observed slightly lower digoxin levels in 1-117 patients. Results showed that in patients receiving digoxin with interrupted dosage regimen post pause digoxin level was statistically significantly lower than pre-pause (p  lt  0.05). Based on multiple linear regression, the ratio of given dose and trough concentration was mainly predicted by clearance creatinine, and to lesser extent by patient's ideal body weight. Interrupted dosing schedule shows greater variability in drug levels comparing to continuous dosing, and it additionally causes difficulties in reaching and maintaining steady trough levels between doses. Hence, individualization of dosing regimen should he carefully guided based on target levels and not solely on clinical signs and symptoms.",
publisher = "Polskie Towarzystwo Farmaceutyczne, Warsaw",
journal = "Acta Poloniae Pharmaceutica - Drug Research",
title = "The posology and trough concentrations of digoxin in adult and elderly patients",
volume = "73",
number = "5",
pages = "1361-1368",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2667"
}

Bajraktarević, A., Mehmedagić, A., Vučićević, K., Kulić, M.,& Miljković, B.. (2016). The posology and trough concentrations of digoxin in adult and elderly patients. in Acta Poloniae Pharmaceutica - Drug Research
Polskie Towarzystwo Farmaceutyczne, Warsaw., 73(5), 1361-1368.
https://hdl.handle.net/21.15107/rcub_farfar_2667

Bajraktarević A, Mehmedagić A, Vučićević K, Kulić M, Miljković B. The posology and trough concentrations of digoxin in adult and elderly patients. in Acta Poloniae Pharmaceutica - Drug Research. 2016;73(5):1361-1368.
https://hdl.handle.net/21.15107/rcub_farfar_2667 .

Bajraktarević, Azra, Mehmedagić, Aida, Vučićević, Katarina, Kulić, Mehmed, Miljković, Branislava, "The posology and trough concentrations of digoxin in adult and elderly patients" in Acta Poloniae Pharmaceutica - Drug Research, 73, no. 5 (2016):1361-1368,
https://hdl.handle.net/21.15107/rcub_farfar_2667 .

TY  - JOUR
AU  - Golubović, Bojana
AU  - Prostran, Milica
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Grabnar, Iztok
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2678
AB  - Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Medicinal Chemistry
T1  - Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients
VL  - 23
IS  - 19
SP  - 1998
EP  - 2011
DO  - 10.2174/0929867323666151221150214
ER  - 

@article{
author = "Golubović, Bojana and Prostran, Milica and Miljković, Branislava and Vučićević, Katarina and Radivojević, Dragana and Grabnar, Iztok",
year = "2016",
abstract = "Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Medicinal Chemistry",
title = "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients",
volume = "23",
number = "19",
pages = "1998-2011",
doi = "10.2174/0929867323666151221150214"
}

Golubović, B., Prostran, M., Miljković, B., Vučićević, K., Radivojević, D.,& Grabnar, I.. (2016). Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry
Bentham Science Publ Ltd, Sharjah., 23(19), 1998-2011.
https://doi.org/10.2174/0929867323666151221150214

Golubović B, Prostran M, Miljković B, Vučićević K, Radivojević D, Grabnar I. Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry. 2016;23(19):1998-2011.
doi:10.2174/0929867323666151221150214 .

Golubović, Bojana, Prostran, Milica, Miljković, Branislava, Vučićević, Katarina, Radivojević, Dragana, Grabnar, Iztok, "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients" in Current Medicinal Chemistry, 23, no. 19 (2016):1998-2011,
https://doi.org/10.2174/0929867323666151221150214 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Prostran, Milica
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2553
AB  - Since the incidence of obesity continues to increase globally, this source of disposition variability remains a significant issue for clinicians. The prevalence of overweight and obese children has increased worldwide, causing substantial concern over proper therapeutic dosing in this population. Pharmacotherapy in these patients represents a major challenge in the clinical practice, because obese patients are, often excluded from the clinical trials. Consequently, data on drugs' pharmacokinetics (PK) in this population of patients are scarce, incomplete and/or inconclusive. It is previously observed that different degrees of obesity may change the PK profile of drug. Consequently, there is a need for the descriptors of size of the organism that best describes the changes in the composition of the organism in obese patients, and the one that best predicts key PK parameters that define dosage regimen. Changes in PK parameters of certain drugs are clinically important in the obese children and adolescent patients, requiring changes in usual dosage regimen.
AB  - Obzirom da se globalno uočava kontinuiran porast incidence gojaznih osoba, gojaznost kao faktor varijabilnosti u dispoziciji leka postaje vrlo značajan aspekt razmatranja za kliničare. Prevalenca dece sa prekomernom telesnom masom i gojazne dece se povećava u svetu, dovodeći do nedoumica u pogledu pravilnog doziranja lekova u ovoj populaciji. Farmakoterapija ovih pacijenata predstavlja veliki izazov u kliničkoj praksi, jer su gojazne osobe, često isključene iz kliničkih ispitivanja. Stoga, podaci o farmakokinetici (FK) lekova u ovoj populaciji pacijenata su često oskudni, nepotpuni i/ili nisu utemeljeni na jakim dokazima. Primećeno je da različiti stepen gojaznosti može promeniti FK profil leka. Shodno tome, postoji potreba za deskriptorima veličine organizma koji najbolje opisuju promene u sastavu organizma kod gojaznih pacijenata, ali i definisati onaj koji najbolje predviđa vrednosti ključnih parametara FK koji definišu režim doziranja. Promene u FK parametrima određenih lekovakod gojazne dece i adolescenata imaju klinički značaj, što zahteva korekcije uobičajenih režima doziranja.
PB  - Most Art doo, Beograd
T2  - MD - Medical data
T1  - Pharmacokinetic considerations in drug dosing to pediatric obese patients
T1  - Farmakokinetička razmatranja u doziranju lekova pedijatrijskim gojaznim pacijentima
VL  - 8
IS  - 3
SP  - 149
EP  - 153
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2553
ER  - 

@article{
author = "Vučićević, Katarina and Miljković, Branislava and Prostran, Milica",
year = "2016",
abstract = "Since the incidence of obesity continues to increase globally, this source of disposition variability remains a significant issue for clinicians. The prevalence of overweight and obese children has increased worldwide, causing substantial concern over proper therapeutic dosing in this population. Pharmacotherapy in these patients represents a major challenge in the clinical practice, because obese patients are, often excluded from the clinical trials. Consequently, data on drugs' pharmacokinetics (PK) in this population of patients are scarce, incomplete and/or inconclusive. It is previously observed that different degrees of obesity may change the PK profile of drug. Consequently, there is a need for the descriptors of size of the organism that best describes the changes in the composition of the organism in obese patients, and the one that best predicts key PK parameters that define dosage regimen. Changes in PK parameters of certain drugs are clinically important in the obese children and adolescent patients, requiring changes in usual dosage regimen., Obzirom da se globalno uočava kontinuiran porast incidence gojaznih osoba, gojaznost kao faktor varijabilnosti u dispoziciji leka postaje vrlo značajan aspekt razmatranja za kliničare. Prevalenca dece sa prekomernom telesnom masom i gojazne dece se povećava u svetu, dovodeći do nedoumica u pogledu pravilnog doziranja lekova u ovoj populaciji. Farmakoterapija ovih pacijenata predstavlja veliki izazov u kliničkoj praksi, jer su gojazne osobe, često isključene iz kliničkih ispitivanja. Stoga, podaci o farmakokinetici (FK) lekova u ovoj populaciji pacijenata su često oskudni, nepotpuni i/ili nisu utemeljeni na jakim dokazima. Primećeno je da različiti stepen gojaznosti može promeniti FK profil leka. Shodno tome, postoji potreba za deskriptorima veličine organizma koji najbolje opisuju promene u sastavu organizma kod gojaznih pacijenata, ali i definisati onaj koji najbolje predviđa vrednosti ključnih parametara FK koji definišu režim doziranja. Promene u FK parametrima određenih lekovakod gojazne dece i adolescenata imaju klinički značaj, što zahteva korekcije uobičajenih režima doziranja.",
publisher = "Most Art doo, Beograd",
journal = "MD - Medical data",
title = "Pharmacokinetic considerations in drug dosing to pediatric obese patients, Farmakokinetička razmatranja u doziranju lekova pedijatrijskim gojaznim pacijentima",
volume = "8",
number = "3",
pages = "149-153",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2553"
}

Vučićević, K., Miljković, B.,& Prostran, M.. (2016). Pharmacokinetic considerations in drug dosing to pediatric obese patients. in MD - Medical data
Most Art doo, Beograd., 8(3), 149-153.
https://hdl.handle.net/21.15107/rcub_farfar_2553

Vučićević K, Miljković B, Prostran M. Pharmacokinetic considerations in drug dosing to pediatric obese patients. in MD - Medical data. 2016;8(3):149-153.
https://hdl.handle.net/21.15107/rcub_farfar_2553 .

Vučićević, Katarina, Miljković, Branislava, Prostran, Milica, "Pharmacokinetic considerations in drug dosing to pediatric obese patients" in MD - Medical data, 8, no. 3 (2016):149-153,
https://hdl.handle.net/21.15107/rcub_farfar_2553 .

TY  - JOUR
AU  - Ilić, V
AU  - Bogićević, Dragana
AU  - Miljković, Branislava
AU  - Ješić, M
AU  - Kovačević, M
AU  - Prostran, Milica
AU  - Vezmar-Kovačević, Sandra
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2767
AB  - Aim. To identify potential risk factors for the development of subclinical hypothyroidism following long-term valproic acid monotherapy in children with epilepsy. Methods. Serumlevels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine, thyreoglobulin antibodies, and thyroid peroxidase antibodies were determined in 41 patients and in 41 sex- And age-matched healthy children. Results. Meanvalproic acid treatment durationwas 2.80?}1.96 years. The valproic acid group had higher serum thyroid-stimulating hormone (p lt 0.001) and free triiodothyronine (p lt 0.05) levels compared to the control group. Serum thyroid-stimulating hormone and free triiodothyronine were above the upper limit for healthy controls in 34% and 32% of patients, respectively, and no clinical features of thyroid dysfunction were observed. Duration of valproic acid monotherapy for less than four years was a risk factor for elevated thyroid-stimulating hormone levels. Conclusion. One third of children with normal range serum valproic acid levels may have elevated serum thyroid-stimulating hormone and free triiodothyronine levels, especially in the first four years of treatment.
PB  - John Libbey Eurotext
T2  - Epileptic Disorders
T1  - Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy
VL  - 18
IS  - 2
SP  - 181
EP  - 186
DO  - 10.1684/epd.2016.0821
ER  - 

@article{
author = "Ilić, V and Bogićević, Dragana and Miljković, Branislava and Ješić, M and Kovačević, M and Prostran, Milica and Vezmar-Kovačević, Sandra",
year = "2016",
abstract = "Aim. To identify potential risk factors for the development of subclinical hypothyroidism following long-term valproic acid monotherapy in children with epilepsy. Methods. Serumlevels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine, thyreoglobulin antibodies, and thyroid peroxidase antibodies were determined in 41 patients and in 41 sex- And age-matched healthy children. Results. Meanvalproic acid treatment durationwas 2.80?}1.96 years. The valproic acid group had higher serum thyroid-stimulating hormone (p lt 0.001) and free triiodothyronine (p lt 0.05) levels compared to the control group. Serum thyroid-stimulating hormone and free triiodothyronine were above the upper limit for healthy controls in 34% and 32% of patients, respectively, and no clinical features of thyroid dysfunction were observed. Duration of valproic acid monotherapy for less than four years was a risk factor for elevated thyroid-stimulating hormone levels. Conclusion. One third of children with normal range serum valproic acid levels may have elevated serum thyroid-stimulating hormone and free triiodothyronine levels, especially in the first four years of treatment.",
publisher = "John Libbey Eurotext",
journal = "Epileptic Disorders",
title = "Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy",
volume = "18",
number = "2",
pages = "181-186",
doi = "10.1684/epd.2016.0821"
}

Ilić, V., Bogićević, D., Miljković, B., Ješić, M., Kovačević, M., Prostran, M.,& Vezmar-Kovačević, S.. (2016). Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy. in Epileptic Disorders
John Libbey Eurotext., 18(2), 181-186.
https://doi.org/10.1684/epd.2016.0821

Ilić V, Bogićević D, Miljković B, Ješić M, Kovačević M, Prostran M, Vezmar-Kovačević S. Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy. in Epileptic Disorders. 2016;18(2):181-186.
doi:10.1684/epd.2016.0821 .

Ilić, V, Bogićević, Dragana, Miljković, Branislava, Ješić, M, Kovačević, M, Prostran, Milica, Vezmar-Kovačević, Sandra, "Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy" in Epileptic Disorders, 18, no. 2 (2016):181-186,
https://doi.org/10.1684/epd.2016.0821 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Jovanović, Marija
AU  - Golubović, Bojana
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Martinović, Žarko J.
AU  - Prostran, Milica
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2408
AB  - The present study aimed to establish population pharmacokinetic model for phenobarbital (PB), examining and quantifying the magnitude of PB interactions with other antiepileptic drugs concomitantly used and to demonstrate its use for individualization of PB dosing regimen in adult epileptic patients. In total 205 PB concentrations were obtained during routine clinical monitoring of 136 adult epilepsy patients. PB steady state concentrations were measured by homogeneous enzyme immunoassay. Nonlinear mixed effects modelling (NONMEM) was applied for data analyses and evaluation of the final model. According to the final population model, significant determinant of apparent PB clearance (CL/F) was daily dose of concomitantly given valproic acid (VPA). Typical value of PB CL/F for final model was estimated at 0.314 l/h. Based on the final model, co-therapy with usual VPA dose of 1000 mg/day, resulted in PB CL/F average decrease of about 25 %, while 2000 mg/day leads to an average 50 % decrease in PB CL/F. Developed population PB model may be used in estimating individual CL/F for adult epileptic patients and could be applied for individualizing dosing regimen taking into account dose-dependent effect of concomitantly given VPA.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients
VL  - 71
IS  - 2
SP  - 183
EP  - 190
DO  - 10.1007/s00228-014-1778-7
ER  - 

@article{
author = "Vučićević, Katarina and Jovanović, Marija and Golubović, Bojana and Vezmar-Kovačević, Sandra and Miljković, Branislava and Martinović, Žarko J. and Prostran, Milica",
year = "2015",
abstract = "The present study aimed to establish population pharmacokinetic model for phenobarbital (PB), examining and quantifying the magnitude of PB interactions with other antiepileptic drugs concomitantly used and to demonstrate its use for individualization of PB dosing regimen in adult epileptic patients. In total 205 PB concentrations were obtained during routine clinical monitoring of 136 adult epilepsy patients. PB steady state concentrations were measured by homogeneous enzyme immunoassay. Nonlinear mixed effects modelling (NONMEM) was applied for data analyses and evaluation of the final model. According to the final population model, significant determinant of apparent PB clearance (CL/F) was daily dose of concomitantly given valproic acid (VPA). Typical value of PB CL/F for final model was estimated at 0.314 l/h. Based on the final model, co-therapy with usual VPA dose of 1000 mg/day, resulted in PB CL/F average decrease of about 25 %, while 2000 mg/day leads to an average 50 % decrease in PB CL/F. Developed population PB model may be used in estimating individual CL/F for adult epileptic patients and could be applied for individualizing dosing regimen taking into account dose-dependent effect of concomitantly given VPA.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients",
volume = "71",
number = "2",
pages = "183-190",
doi = "10.1007/s00228-014-1778-7"
}

Vučićević, K., Jovanović, M., Golubović, B., Vezmar-Kovačević, S., Miljković, B., Martinović, Ž. J.,& Prostran, M.. (2015). Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 71(2), 183-190.
https://doi.org/10.1007/s00228-014-1778-7

Vučićević K, Jovanović M, Golubović B, Vezmar-Kovačević S, Miljković B, Martinović ŽJ, Prostran M. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. in European Journal of Clinical Pharmacology. 2015;71(2):183-190.
doi:10.1007/s00228-014-1778-7 .

Vučićević, Katarina, Jovanović, Marija, Golubović, Bojana, Vezmar-Kovačević, Sandra, Miljković, Branislava, Martinović, Žarko J., Prostran, Milica, "Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients" in European Journal of Clinical Pharmacology, 71, no. 2 (2015):183-190,
https://doi.org/10.1007/s00228-014-1778-7 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Vovk, Tomaz
AU  - Prostran, Milica
AU  - Erić, Slavica
AU  - Kuzmanovski, Igor
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2366
AB  - Purpose: The application of artificial neural networks in the pharmaceutical sciences is broad, ranging from drug discovery to clinical pharmacy. In this study, we explored the applicability of counter-propagation artificial neural networks (CPANNs), combined with genetic algorithm (GA) for prediction of topiramate (TPM) serum levels based on identified factors important for its prediction. Methods: The study was performed on 118 TPM measurements obtained from 78 adult epileptic patients. Patients were on stable TPM dosing regimen for at least 7 days; therefore, steady-state was assumed. TPM serum concentration was determined by high performance liquid chromatography with fluorescence detection. The influence of demographic, biochemical parameters and therapy characteristics of the patients on TPM levels were tested. Data analysis was performed by CPANNs. GA was used for optimal CPANN parameters, variable selection and adjustment of relative importance. Results: Data for training included 88 measured TPM concentrations, while remaining were used for validation. Among all factors tested, TPM dose, renal function (eGFR) and carbamazepine dose significantly influenced TPM level and their relative importance were 0.7500, 0.2813, 0.0625, respectively. Relative error and root mean squared relative error (%) and their corresponding 95% confidence intervals for training set were 2.14 [(-2.41) - 6.70] and 21.5 [18.5 - 24.1]; and for test set were 6.21 [(-21.2) - 8.77] and 39.9 [31.7 - 46.7], respectively. Conclusions: Statistical parameters showed acceptable predictive performance. Results indicate the feasibility of CPANNs combined with GA to predict TPM concentrations and to adjust relative importance of identified variability factors in population of adult epileptic patients.
PB  - Canadian Soc Pharmaceutical Sciences, Edmonton
T2  - Journal of Pharmacy and Pharmaceutical Sciences
T1  - Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy
VL  - 18
IS  - 5
SP  - 856
EP  - 862
DO  - 10.18433/J33031
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Vovk, Tomaz and Prostran, Milica and Erić, Slavica and Kuzmanovski, Igor and Vučićević, Katarina and Miljković, Branislava",
year = "2015",
abstract = "Purpose: The application of artificial neural networks in the pharmaceutical sciences is broad, ranging from drug discovery to clinical pharmacy. In this study, we explored the applicability of counter-propagation artificial neural networks (CPANNs), combined with genetic algorithm (GA) for prediction of topiramate (TPM) serum levels based on identified factors important for its prediction. Methods: The study was performed on 118 TPM measurements obtained from 78 adult epileptic patients. Patients were on stable TPM dosing regimen for at least 7 days; therefore, steady-state was assumed. TPM serum concentration was determined by high performance liquid chromatography with fluorescence detection. The influence of demographic, biochemical parameters and therapy characteristics of the patients on TPM levels were tested. Data analysis was performed by CPANNs. GA was used for optimal CPANN parameters, variable selection and adjustment of relative importance. Results: Data for training included 88 measured TPM concentrations, while remaining were used for validation. Among all factors tested, TPM dose, renal function (eGFR) and carbamazepine dose significantly influenced TPM level and their relative importance were 0.7500, 0.2813, 0.0625, respectively. Relative error and root mean squared relative error (%) and their corresponding 95% confidence intervals for training set were 2.14 [(-2.41) - 6.70] and 21.5 [18.5 - 24.1]; and for test set were 6.21 [(-21.2) - 8.77] and 39.9 [31.7 - 46.7], respectively. Conclusions: Statistical parameters showed acceptable predictive performance. Results indicate the feasibility of CPANNs combined with GA to predict TPM concentrations and to adjust relative importance of identified variability factors in population of adult epileptic patients.",
publisher = "Canadian Soc Pharmaceutical Sciences, Edmonton",
journal = "Journal of Pharmacy and Pharmaceutical Sciences",
title = "Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy",
volume = "18",
number = "5",
pages = "856-862",
doi = "10.18433/J33031"
}

Jovanović, M., Sokić, D., Grabnar, I., Vovk, T., Prostran, M., Erić, S., Kuzmanovski, I., Vučićević, K.,& Miljković, B.. (2015). Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy. in Journal of Pharmacy and Pharmaceutical Sciences
Canadian Soc Pharmaceutical Sciences, Edmonton., 18(5), 856-862.
https://doi.org/10.18433/J33031

Jovanović M, Sokić D, Grabnar I, Vovk T, Prostran M, Erić S, Kuzmanovski I, Vučićević K, Miljković B. Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy. in Journal of Pharmacy and Pharmaceutical Sciences. 2015;18(5):856-862.
doi:10.18433/J33031 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Vovk, Tomaz, Prostran, Milica, Erić, Slavica, Kuzmanovski, Igor, Vučićević, Katarina, Miljković, Branislava, "Application of Counter-propagation Artificial Neural Networks in Prediction of Topiramate Concentration in Patients with Epilepsy" in Journal of Pharmacy and Pharmaceutical Sciences, 18, no. 5 (2015):856-862,
https://doi.org/10.18433/J33031 . .

TY  - JOUR
AU  - Vezmar-Kovačević, Sandra
AU  - Simisić, Mika
AU  - Stojkov-Rudinski, Svetlana
AU  - Ćulafić, Milica
AU  - Vučićević, Katarina
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2227
AB  - Objectives: The aim of the study was to determine the rate of Potentially Inappropriate Medicines (PIM) and Potential Prescription Omissions (PPO) according to Screening Tool of Older Person's potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment (STOPP/START) criteria. Study Design: A cross-sectional survey in community pharmacy. Method: A prospective cross-sectional study was performed, during March-May 2012, in five community pharmacies. Patients aged >= 65 years, who collected one or more prescribed medications, were asked to participate in the study, and an interview was scheduled. Patients were asked to provide their complete medical and biochemical record from their general practitioner. Results: 509 patients, mean age 74.8 +/- 6.5 years, 57.4% female, participated in the study. 164 PIM were identified in 139 patients (27.3%). The most common were: long-term use of long-acting benzodiazepines (20.7%), use of non-steroidal antiinflammatory drugs (NSAID) in patients with moderate-severe hypertension (20.1%), use of theophylline as monotherapy for chronic obstructive pulmonary disease (COPD, 15.9%) and use of aspirin without appropriate indication (15.2%). Patients with more than four prescpritions had a higher risk for PIM (OR 2.85, 95% CI 1.97-4.14, p lt 0.001). There were 439 PPO, identified in 257, (50.5%) patients. Predictors for PPO were older age, presence of diabetes, myocardial infarction, osteoporosis, stroke, COPD and/or angina pectoris. Conclusion: STOPP/START criteria may be useful in identifying inappropriate prescribing and improving the current prescribing practices. Pharmacists should focus more on patients with more than four medications and/or patients with gout or pain accompanied with arterial hypertension because those patient may be at higher risk of PIM. Additionlly, patients older than 74 years with diabetes, osteoporosis, myocardial infarction, stroke, angina pectoris and/or COPD may have an increased risk of PPO.
PB  - Public Library Science, San Francisco
T2  - PLoS One
T1  - Potentially Inappropriate Prescribing in Older Primary Care Patients
VL  - 9
IS  - 4
DO  - 10.1371/journal.pone.0095536
ER  - 

@article{
author = "Vezmar-Kovačević, Sandra and Simisić, Mika and Stojkov-Rudinski, Svetlana and Ćulafić, Milica and Vučićević, Katarina and Prostran, Milica and Miljković, Branislava",
year = "2014",
abstract = "Objectives: The aim of the study was to determine the rate of Potentially Inappropriate Medicines (PIM) and Potential Prescription Omissions (PPO) according to Screening Tool of Older Person's potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment (STOPP/START) criteria. Study Design: A cross-sectional survey in community pharmacy. Method: A prospective cross-sectional study was performed, during March-May 2012, in five community pharmacies. Patients aged >= 65 years, who collected one or more prescribed medications, were asked to participate in the study, and an interview was scheduled. Patients were asked to provide their complete medical and biochemical record from their general practitioner. Results: 509 patients, mean age 74.8 +/- 6.5 years, 57.4% female, participated in the study. 164 PIM were identified in 139 patients (27.3%). The most common were: long-term use of long-acting benzodiazepines (20.7%), use of non-steroidal antiinflammatory drugs (NSAID) in patients with moderate-severe hypertension (20.1%), use of theophylline as monotherapy for chronic obstructive pulmonary disease (COPD, 15.9%) and use of aspirin without appropriate indication (15.2%). Patients with more than four prescpritions had a higher risk for PIM (OR 2.85, 95% CI 1.97-4.14, p lt 0.001). There were 439 PPO, identified in 257, (50.5%) patients. Predictors for PPO were older age, presence of diabetes, myocardial infarction, osteoporosis, stroke, COPD and/or angina pectoris. Conclusion: STOPP/START criteria may be useful in identifying inappropriate prescribing and improving the current prescribing practices. Pharmacists should focus more on patients with more than four medications and/or patients with gout or pain accompanied with arterial hypertension because those patient may be at higher risk of PIM. Additionlly, patients older than 74 years with diabetes, osteoporosis, myocardial infarction, stroke, angina pectoris and/or COPD may have an increased risk of PPO.",
publisher = "Public Library Science, San Francisco",
journal = "PLoS One",
title = "Potentially Inappropriate Prescribing in Older Primary Care Patients",
volume = "9",
number = "4",
doi = "10.1371/journal.pone.0095536"
}

Vezmar-Kovačević, S., Simisić, M., Stojkov-Rudinski, S., Ćulafić, M., Vučićević, K., Prostran, M.,& Miljković, B.. (2014). Potentially Inappropriate Prescribing in Older Primary Care Patients. in PLoS One
Public Library Science, San Francisco., 9(4).
https://doi.org/10.1371/journal.pone.0095536

Vezmar-Kovačević S, Simisić M, Stojkov-Rudinski S, Ćulafić M, Vučićević K, Prostran M, Miljković B. Potentially Inappropriate Prescribing in Older Primary Care Patients. in PLoS One. 2014;9(4).
doi:10.1371/journal.pone.0095536 .

Vezmar-Kovačević, Sandra, Simisić, Mika, Stojkov-Rudinski, Svetlana, Ćulafić, Milica, Vučićević, Katarina, Prostran, Milica, Miljković, Branislava, "Potentially Inappropriate Prescribing in Older Primary Care Patients" in PLoS One, 9, no. 4 (2014),
https://doi.org/10.1371/journal.pone.0095536 . .

TY  - JOUR
AU  - Jovanović, Marija
AU  - Sokić, Dragoslav
AU  - Grabnar, Iztok
AU  - Prostran, Milica
AU  - Obrenović, Radmila
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2091
AB  - Background: Topiramate (TPM) is a sulfamate-substituted monosaccharide that is structurally different from other antiepileptic drugs. TPM inhibits carbonic anhydrase activity, which is associated with loss of bicarbonate from the kidney and consequently metabolic acidosis or electrolyte imbalance. Objective: The objectives of the study were to investigate the influence of TPM therapy on bicarbonate and potassium levels in adult epileptic patients. Methods: Data were collected from 59 adult patients on monotherapy or co-therapy of TPM and other antiepileptic drugs. Serum bicarbonate and potassium levels were available from all patients. Steady-state TPM trough concentrations were determined in blood samples by high-performance liquid chromatography. Data analysis was performed by SPSS software (version 17, Chicago, IL). Results: Patients were divided into group A (duration of therapy shorter than or equal to 5 years) and group B (duration of therapy longer than 5 years). Significant difference (P  lt  0.05) in serum bicarbonate levels was observed between these 2 groups. Bicarbonate levels were linearly related to the TPM therapy duration. No correlation was found between the TPM dose or patient age and bicarbonate or potassium levels, as well as between therapy duration and potassium level. Linear regression analysis showed no significant association among 54 available TPM trough concentrations and bicarbonate or potassium levels. Conclusions: Results highlight the frequent occurrence of lower bicarbonate level associated with prolonged TPM therapy. Monitoring bicarbonate levels in patients on long-term TPM therapy might be useful.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Annals of Pharmacotherapy
T1  - Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients
VL  - 48
IS  - 8
SP  - 992
EP  - 997
DO  - 10.1177/1060028014534397
ER  - 

@article{
author = "Jovanović, Marija and Sokić, Dragoslav and Grabnar, Iztok and Prostran, Milica and Obrenović, Radmila and Vučićević, Katarina and Miljković, Branislava",
year = "2014",
abstract = "Background: Topiramate (TPM) is a sulfamate-substituted monosaccharide that is structurally different from other antiepileptic drugs. TPM inhibits carbonic anhydrase activity, which is associated with loss of bicarbonate from the kidney and consequently metabolic acidosis or electrolyte imbalance. Objective: The objectives of the study were to investigate the influence of TPM therapy on bicarbonate and potassium levels in adult epileptic patients. Methods: Data were collected from 59 adult patients on monotherapy or co-therapy of TPM and other antiepileptic drugs. Serum bicarbonate and potassium levels were available from all patients. Steady-state TPM trough concentrations were determined in blood samples by high-performance liquid chromatography. Data analysis was performed by SPSS software (version 17, Chicago, IL). Results: Patients were divided into group A (duration of therapy shorter than or equal to 5 years) and group B (duration of therapy longer than 5 years). Significant difference (P  lt  0.05) in serum bicarbonate levels was observed between these 2 groups. Bicarbonate levels were linearly related to the TPM therapy duration. No correlation was found between the TPM dose or patient age and bicarbonate or potassium levels, as well as between therapy duration and potassium level. Linear regression analysis showed no significant association among 54 available TPM trough concentrations and bicarbonate or potassium levels. Conclusions: Results highlight the frequent occurrence of lower bicarbonate level associated with prolonged TPM therapy. Monitoring bicarbonate levels in patients on long-term TPM therapy might be useful.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Annals of Pharmacotherapy",
title = "Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients",
volume = "48",
number = "8",
pages = "992-997",
doi = "10.1177/1060028014534397"
}

Jovanović, M., Sokić, D., Grabnar, I., Prostran, M., Obrenović, R., Vučićević, K.,& Miljković, B.. (2014). Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients. in Annals of Pharmacotherapy
Sage Publications Inc, Thousand Oaks., 48(8), 992-997.
https://doi.org/10.1177/1060028014534397

Jovanović M, Sokić D, Grabnar I, Prostran M, Obrenović R, Vučićević K, Miljković B. Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients. in Annals of Pharmacotherapy. 2014;48(8):992-997.
doi:10.1177/1060028014534397 .

Jovanović, Marija, Sokić, Dragoslav, Grabnar, Iztok, Prostran, Milica, Obrenović, Radmila, Vučićević, Katarina, Miljković, Branislava, "Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients" in Annals of Pharmacotherapy, 48, no. 8 (2014):992-997,
https://doi.org/10.1177/1060028014534397 . .